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DISTRIBUTION AND EFFICACY OF CHEMOTHERAPEUTICS IN THE 
TREATMENT OF PRECLINICAL BRAIN METASTASES OF BREAST 
CANCER 
 
Tori Terrell Hall 
 
Brain metastases are a critical, life-threatening problem for women with advanced 
metastatic breast cancer. Approximately 80% of women with disseminated central lesions 
are unable to survive the first year after diagnosis. Despite the breakdown of the blood-
brain barrier, chemotherapeutics have limited penetration and distribution into brain 
metastases and are unable to induce cytotoxicity in the tumor. Limiting the development 
of new treatments for brain metastases of breast cancer, there are no commercially 
available in vitro models available that accurately model, and mimic the functionality of, 
the in vivo blood-tumor barrier (BTB). In an attempt to address the aforementioned 
problem, the following connected, but independent aims were proposed and completed in 
a novel microfluidic device: (1) Determine the permeability of three passive markers and 
one subject to efflux, in blood-brain barrier (BBB) and BTB models (2) Determine if 
trastuzumab crosses the BBB and BTB barrier in both in vivo and in vitro models (3) 
Evaluate if the microfluidic BBB and BTB models are relevant and comparable to current 
in vivo models. Further, based on the data presented herein, additional questions and trials 
have evolved into an evolution of the current microfluidic chip, discussed in the final 
chapter. This dissertation incorporates multiple innovative and complex experiments, 
which suggest that the current microfluidic chip accurately portrays the BBB and BTB 
when compared to the in vivo barriers, and is a readily available and rapid throughput 




I would like to dedicate this work to Roxie Mae, Jaxson Don, Amelia Jo, and our 
future little(s) that have yet to arrive. I entered graduate school to become the best version 
of me I could be, and you guys push me towards that every single day. You are the 
sunshine of my life, and the joys of my heart. I love each one of you more than words 






First and foremost, I would like to sincerely thank my mentor and advisor, Dr. 
Paul Lockman. Dr. Lockman, I am so thankful for the risk you took on me when you 
offered me a position in your lab back in 2012. The ability to work with you over the last 
five years has been such an incredible honor, and advanced my scientific career in 
insurmountable ways. I want to thank you for allowing me to work on such a dynamic 
and unique project, and for not allowing me to give up in the summer of 2015, when I 
was pregnant with the twins and completely burnt out. The wisdom, mentorship, 
guidance, and inspiration you provided to me on a daily basis allowed me the room to 
improve and discover universal truths, as well as helped establish a solid foundation for 
my professional and scientific development. Thank you for the countless times you 
allowed me to sit in your office and cry and always making time to listen with your roll 
of paper towels tucked away. I know I would not have been able to navigate graduate 
school, each of my projects, two cross country moves, two pregnancies, three kids, and 
establishing (and maintaining) my family, without the unyielding tenderness, support, 
understanding and unprecedented patience you provided me over the last five years. The 
relationship I have with you and Julie is one that I will forever cherish, and I look 
forward to the continuation of that friendship as I take the next step of this journey. 
 
Next I would like to acknowledge and thank each of my committee members for 
their willingness to be a part of my committee and for their contribution to my 
experiences throughout graduate school. Each of you have provided influential 
suggestions that have helped guide each of the projects included in this dissertation, as 
	 v	
well as my overall progression as a professional. Dr. Petros, thank you all for the 
challenging questions, numerous discussions regarding translational research, and how 
each of my projects would successfully translate to the clinic. The passion you exert for 
patients has truly inspired me, and the support and faith you have invested within me has 
encouraged me to uphold excellence in every aspect of my life and career. Dr. Callery, 
thank you for providing me with such a strong platform of encouragement, and for the 
many discussions we had in your office about school, work, life and such; there is no 
doubt that your support has been a significant aid in my time at WVU. Dr. Huber, thank 
you for your valuable contributions and suggestions regarding the blood-brain barrier and 
permeability; your knowledge has undoubtedly helped form and aid in this dissertation. 
Dr. Barr, thank you for your support, encouragement, open door, and willing availability 
to sit and talk with me, regardless of the topic; your wisdom, knowledge, and guidance on 
navigating motherhood, work, and happiness has been an invaluable source throughout 
the last two years and I truly appreciate your insight. 
 
To my lab mates, Dr. Chris Adkins, Afroz Mohammad, and Neal Shah, there is no 
doubt that I have gained immense knowledge from each of you and your willingness to 
aid in different parts of these dissertation. Chris, thank you for accepting me into the lab 
(almost) 5 years ago. I could not have asked for a better senior graduate student to have 
learned techniques, and lab demeanor from. You set an excellent example for Afroz and 
I, and I hope to have passed along the foundation of the lab in such a way that benefits 
Dr. Lockman to the max, as you did to me. Afroz, I will always cherish the last 4 years 
and the friendship we share. Thank you for always being willing to drop whatever you 
	 vi	
were doing at a moment’s notice, to come and assist in whatever I was doing, or needing 
help with (even if it meant you and Neal staying up in the lab until 11 PM with me doing 
ENDLESS serial dilutions of radiation!!). You are the epitome of what one would hope 
to have in a lab mate and, most of all, a friend. You will always have a place to stay in 
Texas J Neal, thank you for your sense of humor, your desire to learn, and your 
camaraderie. You were alongside Afroz and I in many of the crazy things we endured (at 
least for the last year and a half or so) and I thank you for your organization, 
functionality, and crazy taste in music. It definitely made those long hours in the IVIS 
more enjoyable. Thank you all for truly making the lab, and West Virginia, feel like 
family. 
 
I would also like to thank Dr. Mohamed Nounou for his immeasurable guidance, 
the foundation of my my cell culture knowledge, and the countless phone calls and 
emails helping me solve whatever technical issue I may have been having. Nounou, thank 
you and Fatema, for your aid in the trastuzumab project. You will always be a part of my 
family. To Jessica Griffith and Emma Dolan, thank you both for your hard work and your 
assistance throughout your time in the lab. The contributions you both made have 
impacted my work, and my life, in more ways than one. To Dr. Julie Lockman, thank you 
for the fantastic job you did at teaching pharmacology at WTAMU. Had I not taken that 
course with you, I truly don’t believe I would be where I am today. Thank you for your 
passion for teaching, for loving me (and my kids) as fiercely as you have over the last 8 
years, and for the many lunch dates we had leading up to my joining Dr. Lockman’s lab. 
Your friendship helped me through a really rough time in my life, and I sincerely thank 
	vii	
you for that. To Dr. Karen Martin, Dr. Amanda Ammer, Sarah McLaughlin, and Emily 
Ellis, thank you for the morning coffee talks, the uncountable amounts of belly laughs, 
and for the unyielding support in the animal and imaging facilities. You guys are the real 
MVPs and without your contributions, there is no doubt that this work would not have 
been possible. Mandy, 85% of this dissertation would NOT have happened had you not 
helped me in troubleshooting the Sweptfield for months on end, and I thank you 
tremendously for that. 
 
 To my incredible family, no amount of words could truly express the gratitude I 
have for the amount of love and support you all have shown me throughout my time in 
graduate school. I know the decision for us to move from the Texas panhandle to West 
Virginia was a tough one to handle, but you each supported and pushed me to finish 
strong and I am so grateful for that. Mom and Dad, I could not have asked for two better 
role models. You both instilled in me the foundation to believe in myself, to reach for my 
dreams and to never give up, and to above all keep God first. Your love, support, faith, 
and example have unquestionably shaped who I am today and I cannot thank you enough 
for that. This most certainly would not have been possible without your love and support. 
To Buddy and Shawn, thank you for accepting me into your incredible family and for 
loving me so fiercely. Without your immeasurable support and constant encouragement, 
the last three years would not have been as easy as they were. To my sweet Nana and 
Grandmommy, thank you both for the endless amounts of love you imparted on me 
anytime we talked. You both are so much of who I am, and I am so grateful to have been 
raised with such strong, female influences. I love you both more than I can say. I only 
	viii	
wish Papa and Granddaddy were here to see this. To Lance, Lexie, Kody, Keri, Lyndsey, 
and Lucas, thank you all for your witty humor, the perfect group texts, and the countless 
prayers you guys have said on my behalf regarding any exam, qualifier, or presentation I 
endured. I am so fortunate to have been blessed with such incredible siblings and 
siblings-in-law.  
 
To Pat, thank you for the (enormous amount of) emotional support you have 
provided to me for the last 10 years. You are the other pillar in the foundation of my 
being, and I have never ceased in thanking the Lord for placing you in my life. Thank 
you for the constant prayers and unwavering support you have shown me. I love you 
tremendously. 
    
 To my incredible, selfless, servant hearted, stud of a husband, Ryan, the past few 
years have not been without their stresses, but you have never ceased in providing a 
stress-free home full of laughter and joy. There were many times over the last year alone 
that I wanted to give in, but you never stopped encouraging me to achieve all that I could. 
I would not be pursing the career path that I am if I did not have the enormous amount of 
support from you that you’ve relentlessly demonstrated over the course of our marriage. 
Thank you for being my best friend, my favorite date, the one who makes me laugh like 
none other, and my strongest supporter. You are the peace that calms my crazy and my 
tangible grace. You make me a better person, and I feel so honored to be your wife. 
 
	 ix	
 Finally, but most importantly, I would like to thank the Lord for the opportunity 
and blessing I was given at WVU, and for the irreplaceable relationships I have made 
along the way. I owe all that I am and have to God, and I pray to always reflect that in my 
life and career. 
 
“And let us not grow weary of doing good, for in due season we will reap, if we do not 




TABLE OF CONTENTS 
ABSTRACT ……………………………………………………………………………. ii 
DEDICATION ..………………………………………………………………………. iii 
ACKNOWLEDGMENTS ……………………………………………………………. iv  
TABLE OF CONTENTS ……………………………………………………………... x 
LIST OF FIGURES ………………………………………………………………..... xii 
ABBREVIATIONS ………………………………………………………………… xiii 
CHAPTER 
1. INTRODUCTION …………………………………………………………... 1 
1.1. Background  ………………………………………………………… 1 
1.2. Chapter Summaries …………………………………………………. 2 
1.3. References …………………………………………………………... 6 
 
2. MODELING THE BLOOD-TUMOR BARRIER; A  
REVIEW OF THE MOST COMMON IN VITRO 
 DEVICES ……………………………………………………..…...…… 9 
 
2.1. The Blood-Brain Barrier ……………………………..……………... 9 
2.2. The Blood-Tumor Barrier ………………………………………..... 12 
2.3. In Vitro Models ……………………....………………………..…... 12 
2.4. Static Model: Transwells and Their Limitations…….………..…… 16 
2.5. Microfluidic Models ……………...……………………………..… 17 
2.6. References ……………..…………………………………………... 27 
 
3. PERMEABILITY ACROSS THE BLOOD-BRAIN  
	 xi	
BARRIER AND BLOOD-TUMOR BARRIER; A  
NOVEL IN VITRO MODEL ON A CHIP ………………………..…. 40 
 
3.1. Introduction …………………………………………………...…… 40 
3.2. Materials and Methods …………………………………………….. 43 
3.3. Results ………………………………………...…………………… 48 
3.4. Discussion …………………………………………………………. 51 
3.5. References …………………………………………………………. 63 
 
4. TRASTUZUMAB EFFICACY IN AN IN VIVO  
AND IN VITRO MODEL OF BRAIN METASTASES  
OF BREAST CANCER ………………………………………………. 74 
 
4.1. Introduction ………………………………………………………... 74 
4.2. Materials and Methods …………………………………………….. 77 
4.3. Results ……………………………………………………………... 84 
4.4. Discussion …………………………………………………………. 86 
4.5. References ………………………………………………………..... 94 
 
5. CONCLUSIONS AND FUTURE DIRECTIONS ……………………… 103 
5.1. Chapter Conclusions ……………..………………………………. 103 
5.2. Future Directions ………………………………………………… 105 
5.3. References ……………………………………...………………… 116 
 
CURRICULUM VITAE ……………………………………….……………………. 117 
LIST OF FIGURES 
	xii	
3.1: Microfluidic chip schematic and methods ………………………………………… 55 
 
3.2: 3-D confocal image of DAPI labeled HUVECs in apical chamber ……………..… 57 
 
3.3: Diffusion rates of different sized MW tracers in the same model ………………… 58 
 
3.4: Representative time-lapse images showing passive diffusion of Free  
TRD from the outer to the central compartment ………………………………….. 59 
 
3.5: Linear central compartment accumulation of different tracers in the  
BBB and BTB microfluidic chip models …………………………………………. 60 
 
3.6: Rhodamine-123 permeability with and without inhibitors in BBB and  
BTB models ………………………………………………………………..……… 61  
 
4.1: Mechanism of trastuzumab movement …………………………………………… 90 
 
4.2: The distribution of radiolabeled 125I –trastuzumab in various body  
organs, and in normal and tumor brain tissues ……………………………………. 91 
 
4.3: Heterogeneous and limited distribution of 125I-trastuzumab in  
preclinical brain metastases of breast cancer model ……………………………… 92 
 
5.1: Microfluidic BTB device overall modifications …………………………………. 110 
 
5.2: Re-engineering of the BTB microfluidic device to allow  
for real-time TEER measurements ………………………………………………. 111 
 
5.3: Port volumes of the current microfluidic device ………………………………… 112 
 
5.4: Proposed redesign for increased recovery port volumes of  
the microfluidic device …………………………………………………………... 113 
 
5.5: Tumor cell extravasation ………………………………………………………… 114 
 




CNS – Central Nervous System 
BTB – Blood-tumor barrier  
BBB – Blood-Brain Barrier 
TEER – Transendothelial Electrical Resistance 
PDMS – Polydimethylsiloxane 
bEnd3 – Brain endothelial cells 
PC – Polycarbonate  
ACM – astrocyte-conditioned medium 
p-gp – p-glycoprotein 
Rho123 – Rhodamine-123 
HBMEC – human brain microvascular endothelial cells 
Free TRD – Sulforhodamine 101 Acid Chloride 
TRD 3 kDa – Texas Red 3000 MW Dextran 
TRD 70 kDa – Texas Red 70,000 MW Dextran 
HUVECs – Human Umbilical Vein Endothelial Cells 
EBM-2 – Endothelial Basal Medium – 2 
kin – Unidirectional uptake transfer constants 
t-Rho123 – fluorescent trastuzumab-Rho123 
TRD 625 Da – Texas red conjugated 625 MW dextran 
eGFP – enhanced green fluorescent protein 
IP – intraperitoneal 









One of the most critical factors concerning advanced stage breast cancer is the 
incidence of brain metastases. The incidence of brain metastases has risen significantly 
over the past 12 years (Carey, Ewend et al. 2004, Clayton, Danson et al. 2004, Lin, 
Bellon et al. 2004, Tham, Sexton et al. 2006, Smid, Wang et al. 2008, Olson, Abdel-
Rasoul et al. 2013), probably due to successful treatements of the primary disease, 
leading to longer survival times and allowing for an increase in peripheral disease to 
occur. In advanced stage breast cancer, 10-16% of patients develop brain metastases 
(Palmieri, Smith et al. 2006) making breast cancer the second most common cause of 
metastatic brain tumors after lung cancer (10–25%) (Steeg, Camphausen et al. 2011, Lin 
2013, Yeh, Yu et al. 2015). Once a clinically detectable brain metastases is discovered 
and the patient becomes symptomatic, median survival is approximately 4 months 
(Colzani, Liljegren et al. 2011) with less than 2% of women surviving two years post-
diagnosis (Zimm, Wampler et al. 1981).  
 
Despite the increased incidence, and the poor survival prognosis, treatment 
options are limited. Once diagnosed with a central nervous system (CNS) metastases, 
traditional treatment options have included radiation, surgery, and adjunctive systemic 
	 2	
therapy. With regard to chemotherapy, inadequate drug delivery to tumors is because of 
poor penetration of drugs across the blood-tumor barrier (BTB) (Lockman, Mittapalli et 
al. 2010). This could be due to both poor permeability and an inadequate distribution to 
cross the BTB, or to the active efflux of the chemotherapeutics due to efflux transporters 
along the BTB and the individual tumor cells, actively removing the drugs from the brain 
parenchyma and back into the bloodstream once they have successfully crossed the BTB 
(Adkins, Mittapalli et al. 2013). Preclinical development of novel drugs to address these 
issues ultimately fail in clinical trials due to the unavailability of in vitro models that 
successfully predict or mimic the in vivo BTB. 
 
The premise of this dissertation builds upon this significant body of literature 
demonstrating a failure of current chemotherapy regimens in the treatment of brain 
metastases of breast cancer due to poor distribution across the BTB. The specific aims of 
this dissertation were to: (1) Determine the permeability of three passive markers and one 
subject to efflux, in blood-brain barrier (BBB) and BTB models (2) Determine if 
trastuzumab crosses the BBB and BTB barrier through both in vivo and in vitro models 
(3) Evaluate if this microfluidic BBB and BTB models are relevant and compatible to 
current in vivo models. 
 
1.2 Chapter Summaries 
1.2.1 Chapter 2  
 There are multiple preclinical in vitro models available, however the limitations 
of each result in models that do not adequately mimic the in vivo BBB and BTB. In this 
	 3	
chapter we thoroughly review the current static and microfluidic in vitro BBB and BTB 
devices, as well as each of their limitations in preclinical research.  
 























1.2.3 Chapter 4  
Drug and antibody delivery to brain metastases has been highly debatable in the 
literature. The BTB, thought to be somewhat more permeable than the BBB, has shown 
to exhibit highly functioning efflux transporters and barrier functions, limiting delivery of 
these targeted therapies. The purpose of this study was to test the permeability of (1) I125-
trastuzumab in an in vivo, and (2) fluorescent trastuzumab-Rho123 (t-Rho123) in a novel 
in vitro BBB and BTB brain metastases of breast cancer model. In vivo: Human MDA-
MB-231-HER2+ metastatic breast cancer cells were grown and maintained under static 
conditions. Cells were harvested at 80% confluency and prepped for intracardiac 
injection into 20 homozygous female NuNu mice. In vitro: Human umbilical vein 
endothelial cells were grown and maintained under shear stress conditions, co-cultured 
with CTX-TDR2 rat brain astrocytes (BBB) or Met-1 metastatic HER2+ murine breast 
cancer cells (BTB), grown and maintained under static conditions, across a porous 
interface in the outer and central compartments, respectively. Tissue distribution of 125I-
trastuzumab revealed only ~3% of injected dose reached normal brain, with ~5% of 
injected dose reaching the brain tumor. No clear correlation was observed between size of 
metastases and the amount of 125I-trastuzumab localized in vivo. This heterogeneity was 
paralleled in vitro, where the distribution of t-Rho123 from the outer chamber to the 
central chamber of the microfluidic device was qualitatively and quantitatively analyzed 
over time. The rate of t-Rho123 linear uptake in the BBB (0.27 ± 0.33 X 104) and BTB 
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(1.29 ± 0.93 X 104) showed to be significantly greater than 0 (p < 0.05). The BTB 
devices showed significant heterogenetic tendencies, as seen in in vivo. This study is one 
of the first studies to measure antibody movement across the blood-brain and blood-
tumor barriers, and demonstrates that, though minute, trastuzumab does cross the blood-
brain and blood-tumor barriers. 
 
1.2.4 Chapter 5 
 The conclusions of each chapter are discussed as well as the results of chapters 3 
and 4, in the form of modifications to the microfluidic device. These modifications were 
developed due to complications and failed experiments within the projects of chapter 3 
and chapter 4. These modifications will result in improvements of different aspects of the 
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CHAPTER 2  
MODELING THE BLOOD-TUMOR BARRIER;  A REVIEW OF THE 
MOST COMMON IN  VITRO  DEVICES  
 
2.1 The Blood-Brain Barrier 
2.1.1 Cellular Function 
The blood-brain barrier (BBB) is a highly controlled and strictly regulated 
complex network of brain microvessels. This barrier is the primary protective interface 
for the brain that functionally restricts ions, molecules, toxins and drug movement from 
blood to the brain parenchyma (Almutairi, Gong et al. 2016). The protective nature of the 
BBB is due in part to the multicellular system (neurovascular unit) that forms it, 
consisting of microvascular brain endothelial cells surrounded by astrocytic foot 
processes, pericytes, neurons, and microglia (Wolff, Antfolk et al. 2015). The first, and 
primary cellular unit of the neurovascular unit are the microvascular brain endothelial 
cells. These specific endothelial cells are noted for their absence of fenestrae and the 
presence of a continuous basement membrane (shared with pericytes) (de Boer and 
Gaillard 2006). These two components are key elements to the highly restrictive nature 
across microvascular endothelial cells when compared to normal endothelial cells. Brain 
microvascular endothelial cells also express a higher than normal amount of tight 
junctions as well as limited pinocytic vesicular transport (Abbott, Patabendige et al. 2010, 
Wolff, Antfolk et al. 2015).  
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The next cellular structure of the neurovascular unit family are the astrocytes. 
Found only in the brain, these cells provide much needed biochemical support to the 
BBB through contact to the microvascular brain endothelial cells with their multiple foot 
processes (Taber and Hurley 2008). This biochemical support has been previously 
studied, and has well established the importance of astrocytes to the integrity of the BBB 
(Abbott 2002) and paracellular movement (Zheng, Aschner et al. 2003), as well as the 
secretion of various factors required for successful BBB function (Janzer and Raff 1987, 
Siddharthan, Kim et al. 2007, Colgan, Collins et al. 2008).  
 
Pericytes are the third cellular structure, and they cover approximately 22%-33%, 
or one fifth to one third, of the basolateral portion of a capillary (Kim, Tran et al. 2006). 
Pericytes have multiple functions; they have been shown to induce the polarity of 
astrocytes leading to a tightening of the BBB (Allt and Lawrenson 2001), affect the 
integrity of the BBB through direct contact with the endothelial cells (Hayashi, Nakao et 
al. 2004), and may play a role in angiogenesis (Daneman, Zhou et al. 2010). Pericytes 
also inhibit the expression of molecules known to increase vascular permeability 
(Daneman, Zhou et al. 2010), while a deficiency of pericytes has been linked to an 
increase in permeability of the BBB (Armulik, Genove et al. 2010).  
 
The last two cells related to the neurovascular unit composing the BBB are 
neurons and microglia. Neurons, the main functional cells of the brain, communicate 
through different chemical and electrical signals. These signals rely on the movement of 
small ions, which aids in the overall maintenance of stable membrane potentials (Abbott 
11	
2013). The presence of neurons has also been shown to increase the integrity of the BBB 
(Minami 2011), which helps maintain the homeostasis of the brain, and protect the brain  
from the influx and efflux of ions. Microglia, the final member of the neurovascular unit, 
are found in the perivascular space and are the immune cells of the central nervous 
system (CNS), meaning they simply clear away debris and apoptotic cells from the brain 
(Sumi, Nishioku et al. 2010).  
 
2.1.2 Restrictions and Permeability 
Within the neurovascular unit, tight junctions at the level of the endothelia play a 
major role in the protective nature of the BBB. Tight junctions are a hallmark of the 
BBB, and are composed of claudins, occludins, and junctional adhesion molecules. These 
junctions seal the microvascular endothelial cells together, creating a physical barrier that 
aids in the regulation of drugs, oxygen, nutrients, ions and pathogens from systemic 
circulation to the brain (Petty and Lo 2002). Tight junctions also restrict paracellular 
transport, or the movement through the intracellular space between cells. Paracellular 
transport is a passive pathway and relies on concentration gradients and permeability, 
causing it to be a slow method of transport (Pardridge 1999). Due to tight junctions 
tightly restricting the paracellular movement between endothelial cells, an alternative 
mechanism to circumvent the BBB is through transcellular transport. Transcellular 
pathways, or the movement through a cell, are energy dependent and substrate specific 
(Mager, Meyer et al. 2016). For example, lipophilic molecules can cross the BBB 
through transendothelial receptor-mediated transport (Schinkel 1999, Vorbrodt and 
Dobrogowska 2003, Roberts, Black et al. 2008, Abbott, Patabendige et al. 2010).  
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2.2 The Blood-Tumor Barrier 
 Once a metastatic tumor cell extravasates from the primary tumor location, it 
enters the bloodstream and travels to a secondary location, where it embeds and begins to 
establish its own blood supply (Carmeliet and Jain 2000, Talmadge and Fidler 2010, 
Eichler, Chung et al. 2011). This process causes a change in the barrier, from the blood-
brain barrier to the blood-tumor barrier (BTB). A tumor’s blood supply may develop 
through a couple of mechanisms: vasculogenesis, angiogenesis, and co-option being the 
main forms. During development, new blood vessels are formed in a process called 
vasculogenesis. Tumor cells have been observed mimicking endothelial cells and forming 
vascular vessels themselves through the use of cancer stem cells or tumor initiating cells 
(Krishna Priya, Nagare et al. 2016). Angiogenesis is the secretion of vascular endothelial 
growth factor by the tumor cell to form sprouts from existing blood vessels (Carmeliet 
and Jain 2000, Folkman 2007, Carmeliet and Jain 2011). Tumor cells can also grow 
along an existing blood vessel instead of sprouting new blood vessels in a mechanism 
known as co-option (Frentzas, Simoneau et al. 2016). After a tumor establishes a blood 
supply, the only thing left is to grow. Tumor permeability, or the leakiness of a tumor, is 
affected by how many fenestra are present in the BTB, and the spatial distribution of, or 
distance between, the tumor vasculature. 
 
2.3 In Vitro Models 
2.3.1 Basic Premise 
The best way to study molecular transport across the BBB is in vivo, or studies in 
the animal’s natural environment, however only ~50% of these results are translational to 
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human (Perel, Roberts et al. 2007). Since in vivo studies are difficult and expensive, in 
vitro models are utilized. In vitro BBB models should, ideally, mimic the structural and 
functional properties of the in vivo BBB and meet the following four requirements: 1) 
Tight junction expression should result in a very restricted barrier. 2) Correct placement 
(luminal vs. abluminal) of influx and efflux transporters, as well as the functionality of 
each transporter compared to the in vivo BBB (Roberts, Black et al. 2008). 3) 
Permeability across the BBB and BTB should be comparable to in vivo (Adkins, 
Mittapalli et al. 2013). 4) Replication of shear stress and vascular flow (Ballermann, 
Dardik et al. 1998, Tarbell 2010, Cucullo, Hossain et al. 2011).  
 
Shear stress and vascular flow dramatically alters the morphology of endothelial 
cells when compared to static cells (Cucullo, Hossain et al. 2011, Prabhakarpandian, 
Shen et al. 2013, Deosarkar, Prabhakarpandian et al. 2015) (SynVivo Chapter 3). Without 
the added shear stress of vascular flow, endothelial cell morphology is described as flat 
and small, with an increased presence of endocytic vesicles, microfilaments and 
clatherin-coated pits (Ballermann and Ott 1995). However, through the addition of 
vascular flow, shear stress alters the endothelial cellular morphology through the 
elongation and increase in size of the endothelia, as well as a decrease in the presence of 
endocytic vesicles, microfilaments, and clatherin-coated pits. There is documented 
evidence also showing a correlated increase in the strength of tight junctions between 
endothelial cells with the addition of shear stress (Collins, Cummins et al. 2006, Colgan, 
Ferguson et al. 2007, Siddharthan, Kim et al. 2007).  
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Every in vitro model includes the same basic parameters: barrier cells, 
extracellular matrix, and a brain microenvironment (Stanimirovic, Bani-Yaghoub et al. 
2015). The barrier cells are grown on semipermeable membrane dividing the basolateral 
and apical compartments, which are located on one side (apical) of the extracellular 
matrix. The extracellular matrix is located on a semipermeable membrane, which 
separates the brain microenvironment (basolateral) and the barrier cells. When studying 
permeability, drugs are placed in the apical compartment and the movement is measured 
in the basolateral compartment, and studied over time. These models have previously 
been studied in a 6-96 well format, and can be miniaturized through the use of 
microfluidics to increase throughput and mimic shear stress as seen in vivo.  
 
2.3.2 Cell Culture Options 
In any in vitro system, there is the option of monoculture, co-culture, or triple 
culture of the cells (Wolff, Antfolk et al. 2015). One of the most widely and easily used 
in vitro systems is a monoculture system. In this system, the only cells used are 
endothelial cells, grown on the apical side of the model, occasionally with the addition of 
astrocyte-conditioned media, which has been shown to increase barrier function 
(Siddharthan, Kim et al. 2007). However, despite having only one cell type, the absence 
of astrocytes makes this model undesirable due to the vast amount of data showing the 
importance of astrocytes to the integrity of the BBB (Abbott 2002, Abbott, Patabendige 
et al. 2010, Abbott 2013). The next step in the in vitro model system is the co-culture 
system: contact co-culture or noncontact co-culture. Depending on the type of model, the 
transendothelial electrical resistance (TEER) will vary. TEER is a quantitative technique 
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used to measure the tightness of the seal between endothelial cells (created by tight 
junctions) and is a good indicator of the functionality of the BBB. The higher the TEER 
value, the stronger the integrity of the barrier is thought to be.  In a contact co-culture 
system, endothelial cells are grown as in the monoculture model, with 
astrocytes/pericytes/neurons grown on the bottom of the porous membrane (if in a 
transwell) or in the basolateral chamber, where they are able to have direct contact with 
the endothelial cells. Through direct contact with the secondary cells, the TEER values 
for endothelial cells have been shown to increase by upwards of nine times higher, in 
comparison, to the monoculture model (Gaillard, Voorwinden et al. 2001, Nakagawa, 
Deli et al. 2009).  
 
In contrast, a noncontact co-culture system is where the 
astrocytes/pericytes/neurons are grown on the bottom of the 6-96 well plate, not in direct 
contact with the endothelial cells. Morphological, chemical, and biological changes can 
be observed due to the chemical gradient, with TEER values reportedly increased by a 
factor of 2 in comparison to the monoculture model (Nakagawa, Deli et al. 2009). The 
last, most complicated, model is the triple culture. There are a couple of options with this 
model: 1) Endothelial cells are in direct contact with astrocytes and indirect contact with 
neurons, showing a 35.9% increase in TEER when compared to monoculture (Xue, Liu et 
al. 2013). 2) Endothelial cells are in direct contact with pericytes and indirect contact 
with astrocytes, where an eight-fold increase in TEER is observed in comparison to the 
monoculture model (Nakagawa, Deli et al. 2007).  
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2.4 Static Model: Transwells and Their Limitations 
 When choosing an in vitro model, the desire is to find a model that cultures pure 
cell types resulting in high TEER values with low permeability. There are a couple 
options when choosing an in vitro BBB/BTB model: static or microfluidic models. 
Transwells are the most widely used and commercially available static in vitro models to 
study diffusional movement across endothelia are transwell systems. Briefly, it consists 
of an upper chamber with endothelia grown on top of a porous membrane, which resides 
above a lower chamber containing astrocytes/neurons for a blood-brain barrier (BBB) 
model and cancer cells for a BTB model (Bicker, Alves et al. 2014, Czupalla, Liebner et 
al. 2014, Srinivasan, Kolli et al. 2015, Helms, Abbott et al. 2016). Permeation of 
molecules and or cells is evaluated by calculating accumulation/distribution between 
compartments.  
 
The transwell model has limitations that result in calculation errors in drug 
movement, as well as increased apparent permeability rates due to the endothelia (upper 
chamber) having gaps between cells near the insert edge (Noseda, Chang et al. 2004, 
Santaguida, Janigro et al. 2006), and because of the lack of flow associated sheer stress 
which decreases tight junction formation (Prabhakarpandian, Shen et al. 2013, Czupalla, 
Liebner et al. 2014, Deosarkar, Prabhakarpandian et al. 2015, Helms, Abbott et al. 2016). 
Another limitation is the ten-fold difference in drug diffusion calculations when 
compared to “proportional” in vivo measurements due to the presence of an unstirred 
water layer above the endothelial surface. This unstirred water layer results in increased 
permeability for hydrophilic drugs and decreased permeability for lipid soluble drugs 
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(Barry and Diamond 1984, Noseda, Chang et al. 2004, Prabhakarpandian, Shen et al. 
2013, Czupalla, Liebner et al. 2014, Deosarkar, Prabhakarpandian et al. 2015).  
 
2.5 Microfluidic Models 
Microfluidic devices are still early in the BBB field and aren’t as widely used as 
transwells due to their price, lack of commercial availability, and issues for researchers to 
master (Stanness, Guatteo et al. 1996, Lippmann, Azarin et al. 2012). Despite not being 
as well used, the basic premise for most microfluidic devices is still the same. As with 
transwells, endothelial cells are co-cultured in a luminal (apical) compartment with 
astrocytes, or the secondary cells of choice, are seeded on the basolateral side of the 
lumen. After all cells have been established and allowed to grow in static conditions, 
vascular flow is exerted in the apical chamber for a set amount of time, and permeability 
studies are allowed to commence through the flow of tracer through the apical chamber 
with samples taken from the basolateral chamber. 
 
In recent years static co-culture has begun to fall by the wayside with the advent 
of more physiologically relevant models. There has been a great deal of work in the 
realms of microfluidics, or lab-on-a-chip technologies, in order to address some of the 
known shortcomings of other in vitro models. The push to establish a reliable and 
replicable microfluidic BBB has quickly produced a wide variety of models, most of 
which incorporate consistent flow in order to promote the expression of tight junctions in 
cultured endothelial cells and more closely mimic the in vivo BBB, though these models 
are not without their own difficulties and shortcomings (van der Helm, van der Meer et 
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al. 2016). To characterize these models, investigators employ similar quantifying 
methods as those used to characterize transwells and other static cultures. These methods 
include: TEER, immunofluorescent staining of tight junctions, cell viability assays, and 
measurement of the permeability of various compounds, which may then be compared to 
in vivo values and other static in vitro models (Lockman, Mittapalli et al. 2010, Adkins, 
Mittapalli et al. 2013, Thomsen, Burkhart et al. 2015). For this review, we have selected a 
number of models representing the wide diversity of approaches to creating a 
microfluidic BBB. 
 
2.5.1 Stacked Compartmental Designs 
One of the first viable models of microfluidic tissue culture developed specifically 
to model the BBB was developed by Booth and Kim in 2012 (Booth and Kim 2012). 
Their model utilized stacked polydimethylsiloxane (PDMS) culture chambers separated 
by a perforated membrane. These separate chambers allowed for separate culture of 
astrocytes (C8D1A) and brain endothelial cells (bEnd3), as well as their biochemical 
communication through the membrane, which has also been previously observed with 
transwell models (Booth and Kim 2012). Electrodes were incorporated to allow for 
TEER measurements. Nearly all endothelial cells seeded in the device remained viable 
and expressed tight junctions after 3 days under continuous flow of 2.6 mL min-1 (Booth 
and Kim 2012). Their static control, traditional transwells, exhibited TEER values around 
25 Ω cm2, and a significant increase in TEER when dynamic flow was incorporated in 
their chip model, over 250 Ω cm2 (Booth and Kim 2012). They also showed a significant 
improvement in TEER values from a bEnd3 monolayer in their chip device, nearly 175 Ω 
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cm2, to devices in co-culture with steady-state TEER values at more than 250 Ω cm2  
(Booth and Kim 2012). 
 
Many other models utilize PDMS superstructure because it is optically 
transparent, inexpensive, can be adapted to virtually any 3D-printed silicon cast, and is 
relatively expedient in production, as a 10:1 mixture of base to curing agent can cure in 
approximately 1h (Yeon, Na et al. 2012, Achyuta, Conway et al. 2013, Griep, Wolbers et 
al. 2013, Prabhakarpandian, Shen et al. 2013, Brown, Pensabene et al. 2015, Cho, Seo et 
al. 2015, Deosarkar, Prabhakarpandian et al. 2015, Sellgren, Hawkins et al. 2015, Wang, 
Khafagy el et al. 2016). In 2013, Achyuta et al. also developed a vertically stacked 
PDMS compartment device. However, their approach required the separate culture of 
RBE4 endothelial and primary rat cortical cells in their respective chambers before 
stacking the components brought them into a co-culture environment, in which the flow 
over the endothelial cells was approximately 17 µL min-1 (Achyuta, Conway et al. 2013). 
The TEER of the barriers in these devices could not be measured, as no electrodes were 
incorporated into the device, but the in vitro BBB displayed appropriate physiological 
responses to TNFα stimulation, namely increased permeability to a 3kDa AlexafluorTM-
conjugated dextran (Achyuta, Conway et al. 2013). Endothelial cells were also confirmed 
to express tight-junction protein ZO-1, which was elevated in the presence of astrocyte–
conditioned medium (ACM) (Achyuta, Conway et al. 2013).  
 
One of the most recent stacked PDMS devices was developed by Sellgren et al. in 
2015. They also cultured cells in stacked PDMS chambers separated by 0.4 µm porous 
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membranes of two different materials: nanopourous Teflon and polycarbonate (PC). 
Rather than seeding their C8D1A astrocytes on one side of the membrane directly, they 
suspended the cells in a collagen matrix and injected them into the device before seeding 
the bEnd3 cells on the opposite side of the membrane (Sellgren, Hawkins et al. 2015). 
The endothelial cell chamber was 150 µm in diameter, the size of a vessel much larger 
than human brain capillaries, which average approximately 10 µm in diameter (Wong, 
Ye et al. 2013). However, they still achieved near physiological shear stress at 5 dyn cm-2 
with a flow rate of 120 µl min-1. Their model displayed distinct tight junction expression 
through the staining of claudins, and also a significantly tighter barrier than those 
observed in static transwell cultures, and the two membrane materials were comparable 
(Sellgren, Hawkins et al. 2015). 
 
Other stacked devices have been produced, and though they fail to recapitulate the 
cylindrical shape of capillaries and the brain tissue surrounding them, some have made 
very promising strides in the improvement of in vitro BBB models. Wang et al. fabricated 
a device using a 3D printer to deposit Objet VeroClear photopolymer to create a set of 
stacked compartments for cell culture and media storage (Wang, Khafagy el et al. 2016). 
Their model utilized a rocking table rather than a perfusion pump to move media across 
the surface of BMECs differentiated from human pluripotent stem cells, which were 
maintained in co-culture with primary rat astrocytes (Wang, Khafagy el et al. 2016). 
Without the magnitude of shear stress induced in other models to promote formation of 
tight junctions, their chip devices still maintained TEER values of 3000 Ω cm2 (Wang, 
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Khafagy el et al. 2016), some of the closest to in vivo values seen in an in vitro model, 
which they credit to . This may be due to the origin of their cells, which is unique. 
 
2.5.2 Horizontal Layouts 
Another set of PDMS models have been designed with a horizontal layout. A 
number of microfluidic models have been developed using devices produced by SynVivo 
Corporation. Prabhakarpandian et al. created their SymBBB using a PDMS 
superstructure mounted to a glass microscope slide (Prabhakarpandian, Shen et al. 2013). 
It was seeded with rat brain endothelial cells (RBE4) and perfused with ACM at a rate of 
0.1 µl min-1. Bifurcated apical chambers were separated from a central basolateral 
chamber by a 100 µm section of PDMS perforated with 3µm gaps to allow for passive 
diffusion (Prabhakarpandian, Shen et al. 2013). Though their chip did not include 
electrodes for TEER evaluation, they could be imaged to show real-time diffusion and 
permeability of fluorescent tracer (Prabhakarpandian, Shen et al. 2013). They assessed 
transwell permeability of 3-5kDa FITC-dextran over time and compared it to their 
device, showing a significant decrease in permeability in the microfluidic model both 
with and without ACM (Prabhakarpandian, Shen et al. 2013). It was also observed that 
cells cultured in their device with ACM exhibited normal P-glycoprotein (p-gp) efflux of 
Rhodamine-123 (Rho123), and an increased permeability of Rho123 through the RBE4 




An additional set of experiments by Deosarkar et al. demonstrated the 
development of a neonatal rat BBB in another variation of a SynVivo microfluidic chip. 
The device contained two separate apical chambers and a circular central basolateral 
chamber, and these chambers were separated by a section of PDMS with the same 3µm 
gaps as the aforementioned device (Deosarkar, Prabhakarpandian et al. 2015). The 
devices were seeded with primary neonatal rat astrocytes and primary neonatal Rat brain 
endothelial cells which, after attachment, were maintained under a constant flow of 0.01 
µl min-1 (Deosarkar, Prabhakarpandian et al. 2015). To assess permeability, 40kDa Texas 
Red dextran was perfused into the device at a rate of 0.2 µl min-1 for 90 minutes. They 
performed these experiments as well as ICC on cells in a variety of environments (with 
primary astrocytes, with ACM, and with primary neonatal rat brain endothelial cells 
alone) and found a significant decrease in permeability and an increase in the expression 
of tight junction protein ZO-1, which was dependent on the presence of astrocytes or 
ACM (Deosarkar, Prabhakarpandian et al. 2015). Barrier tightness was also assessed 
through electrical resistance and, again, increased with the presence of astrocytes and 
ACM (Deosarkar, Prabhakarpandian et al. 2015). However, these values cannot, as of 
now, be compared to TEER values from transwells or other models, due to the novel 
methodology and equipment used to acquire the measurements (Deosarkar, 
Prabhakarpandian et al. 2015). 
 
2.5.3 Hollow Fibrous Cellular Supports 
Another model, produced by Herland et al. in 2016, utilizes a combination of 
PDMS super structure and a hollow tube of collagen fibers for cell support. Within what 
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amounts to a simple PDMS box, they used a collagen matrix with suspended human 
astrocytes to form a cylindrical vessel (Herland, van der Meer et al. 2016). They then 
seeded human pericytes in two stages, flipping the device over in each stage to form a 
full cylindrical monolayer of the cells, and followed with the seeding of human brain 
microvascular endothelial cells (HBMEC) (Herland, van der Meer et al. 2016). In this 
way, they created a softer, more physiologically relevant structure than other PDMS 
models while also incorporating all three structural components of brain microvessels 
(Herland, van der Meer et al. 2016). At a flow of 120 µL min-1, they achieved a shear 
stress of 1 dyne cm-2, which is low in comparison to physiological conditions.  
 
They measured barrier tightness using 3 kDa-Alexa488 Dextran diffusion, as 
TEER electrodes could not be reliably incorporated into their collagen gels (Herland, van 
der Meer et al. 2016). They also assessed the inflammatory response of the in vitro 
vessels to TNFα and stained for tight junction proteins (Herland, van der Meer et al. 
2016). They then compared their dynamic model to transwells seeded with the same 
cells. Though their study focused on the particular effects of the presence of astrocytes or 
pericytes, rather than the creation of a physiologically relevant model with a sufficiently 
tight barrier, they did observe distinct expression of tight junctions (Herland, van der 
Meer et al. 2016). They also found that their model responded differently to inflammation 
than transwells, with the synthetic vasculature exhibiting a lower fold-increase in 
inflammatory cytokines released after stimulation with TNFα (Herland, van der Meer et 
al. 2016).  
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Other models have built on a variety of materials for cell support. Cucullo et al. 
built upon previous capillary models (Cucullo, McAllister et al. 2002) and also used two 
sets of hollow polypropylene fibers housed in sealed chambers and connected by gas 
permeable silicon tubing (Cucullo, Hossain et al. 2013). The abluminal surface of each 
hollow fiber was coated with fibronectin to promote endothelial cell adhesion, and the 
outer surface was coated with poly-D-lysine to allow for the attachment of astrocytes 
(Cucullo, Hossain et al. 2013). In one chamber, which contained n=3 hollow fibers, 
HBMECs were seeded on the abluminal surface of each hollow fiber, and human 
astrocytes were seeded on the external surface (Cucullo, Hossain et al. 2013). In the other 
chamber, hollow fibers were seeded with HBMECs and human brain vascular smooth 
muscle cells rather than astrocytes (Cucullo, Hossain et al. 2013). These two chambers 
were sealed and connected with silicon tubing to a reservoir of media and a pulsatile 
pump, which delivered a flow of media which was gradually increased from a low shear 
stress of 1 dyne cm-2 to what was comparable to a physiologically relevant blood pressure 
(80-300mmHg)(Cucullo, Hossain et al. 2013).  
 
This complex model of brain vasculature was then characterized by a variety of 
experiments: TEER, molecular permeability assays, response to a hyperosmolar agent, 
and the determination of metabolic activity (Cucullo, Hossain et al. 2013). TEER values 
achieved by this system approached 800 Ω cm2 in the capillary component, whereas the 
venule chamber did not achieve TEER above 250 Ω cm2(Cucullo, Hossain et al. 2013). 
They measured permeability of Diazepam, phenytoin, and sucrose, showing a greater 
permeability of each of these molecules in the venule segment in comparison to the 
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capillary compartment, an observation consistent with in vivo physiology (Cucullo, 
Hossain et al. 2013). When exposed to a hyperosmolar agent, in this case 1.6M mannitol, 
which is sometimes used to increase the permeability of chemotherapeutics, the agent 
induced same opening of the in vitro vascular model as has been observed in vivo 
(Cucullo, Hossain et al. 2013). Finally, their bioenergetic assessment revealed that the 
capillary segment favored aerobic respiration while the venule segment, which was 
exposed to lower shear stress, favored anaerobic respiration (Cucullo, Hossain et al. 
2013). However, they note that further experiments should be completed to confirm these 
results and possible reasons for them.  
 
2.5.4 Cancer Monoculture and Drug Screening Design 
Other microfluidic devices aimed at brain cancer do not incorporate endothelial 
cells with BBB-like properties as a barrier. Rather they use only cancer cells to grow 
tumors under fluid flow to assess the effectiveness of various therapeutics. For example, 
in 2016, Fan et al. developed a microfluidic platform for high-throughput screening of the 
effectiveness of drugs on a glioblastoma cell line (Fan, Nguyen et al. 2016). They used 
poly(ethelene) glycol diacrylate superstructure, to more closely imitate an ECM, and 
grew U87 glioblastoma multiforme cells in sphereoid masses in each microwell within 
the chip (Fan, Nguyen et al. 2016). They then characterized diffusion of dyes to assess 
fluid dynamics, and they treated cells with the conventional chemotherpeutics irinotecan 
and pitavastatin individually and in combination. They observed predicted cell death, and 
they could determine drug concentrations at each time point. Their matrix, however, did 
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absorb some of the drugs, and therefore released them back into the media over time, 
adding another unique variable to their device (Fan, Nguyen et al. 2016).  
 
This type of model has the potential to expedite the introduction of personalized 
medicine and may be a high-throughput alternative for the screening of novel 
compounds, which may be highly effective at treating particular cancers. However, 
without the incorporation of BBB-like membranes to assess drug permeability and the 
ultimate concentrations which may be available after crossing the BBB, these assays are 
largely irrelevant for assessments of novel therapeutics metastatic brain cancers and for 
patients who have been diagnosed with them. Therefore, models that incorporate not only 
a cancer cell line, but also an endothelium with BBB-like properties, should be pursued.  
 
In addition, though many of these models conceptually improve upon transwell 
culture by bypassing the issues of unstirred water layers and unreliable concentration 
gradients, and they incorporate other means of BBB recapitulation such as fluid flow, 
many of them do not significantly improve barrier tightness in comparison to some 
transwell models, which have recently reported maximum TEER values in excess of 
1000 Ω cm2 (Patabendige, Skinner et al. 2013). Further, many are so complex, they 
require extended amounts of time to produce, seed, and reach the steady states necessary 
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CHAPTER 3  
PERMEABILITY ACROSS THE BLOOD-BRAIN BARRIER AND 




The occurrence of brain metastases in breast cancer patients is approximately 
10%-16% (Lin, Amiri-Kordestani et al. 2013). Due to improvements in chemotherapy the 
overall survival of breast cancer patients has increased. Unfortunately with prolonged 
survival the incidence of patients developing symptomatic brain metastases has 
increased. One of the leading complications of brain metastases is the inability of drugs 
to reach the tumor at dosage levels equivalent to adequately induce cytotoxicity. This is 
due, in part, to the presence of a partially intact blood-brain barrier (BBB). 
 
3.1.1 The Blood-Brain Barrier 
The BBB is a complex anatomical network, functioning to strictly regulate the 
movement of molecules, and ions from the blood to the brain, and back. In addition, the 
BBB serves as the conduit to supply the brain with the essential nutrients it needs, while 
facilitating the excretion of waste products through efflux (Abbott, Ronnback et al. 2006, 
Daneman and Prat 2015). The hallmark of the BBB is the presence of endothelial cells 
that are tightly connected by tight junction protein complexes, composed of claudins, 
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occludins, and junction adhesion molecules (Serlin, Shelef et al. 2015).  In addition to 
endothelia, the BBB has a thick basal membrane with pericytes and astrocytic foot 
processes in close proximity (Golden and Pardridge 1999, Pardridge 2005). The net effect 
of this anatomical structure results in the transendothelial electrical resistance (TEER) of 
brain capillaries being ~2,000 ohm*cm2, in comparison to 2-20 ohm*cm2 in peripheral 
capillaries (Crone and Christensen 1981, Olesen and Crone 1983).   In addition to the 
structural components, the BBB his highly enriched in efflux transporters that actively 
restrict the entry a large and diverse set of lipophilic solutes from accumulating in the 
brain (Loscher and Potschka 2005, Loscher and Potschka 2005, Shen and Zhang 2010, 
Adkins, Mittapalli et al. 2013).  
 
3.1.2 The Blood-Tumor Barrier 
When metastatic cancer cells invade the central nervous system (CNS) they may 
eventually colonize and begin to proliferate into a larger tumor mass. Once the lesion has 
grown to a point that it has areas of hypoxia, the tumor will secrete high amounts of 
vascular endothelial growth factor in an attempt to develop a new blood supply (Folkman 
1971, Ferrara and Davis-Smyth 1997, Neufeld, Cohen et al. 1999, Plate, Scholz et al. 
2012). This vasculature (blood-tumor barrier; BTB) is different than the BBB 
predominantly because the astrocytes, pericytes and neurons are no longer in close 
proximity to the capillary.  It is hypothesized that these anatomical changes result in 
vasculature that has greater permeability than the BBB (Henson, Cordon-Cardo et al. 
1992, Hobbs, Monsky et al. 1998, Liebner, Fischmann et al. 2000, Abbott, Ronnback et 
al. 2006, Deo, Theil et al. 2013). The BTB may also have a somewhat different and 
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varied expression of efflux transporters depending on the CNS malignancy (Sawada, 
Kato et al. 1999, Tews, Nissen et al. 2000, Demeule, Shedid et al. 2001, Lockman, 
Mittapalli et al. 2010). Despite the apparent breakdown of the BBB in the presence of a 
tumor, the BTB still limits drug movement in to the CNS lesion substantially greater than 
in peripheral tumors. 
 
3.1.3 In vitro vs in vivo BBB and BTB Models 
Currently, there are no widely validated in vitro models of the BTB.  The most 
widely used in vitro BBB model, that has been somewhat used to model the BTB, is a 
transwell insert system. Briefly, the model consists of upper chamber with endothelial 
cells grown on the surface separated from a lower chamber that may or may not have 
astrocytes and or cancer cells grown in separated by a porous membrane (Bicker, Alves 
et al. 2014, Czupalla, Liebner et al. 2014, Srinivasan, Kolli et al. 2015, Helms, Abbott et 
al. 2016).  Drug movement is modeled by measuring accumulation in the lower chamber 
versus time.  The transwell model has limitations. First, there is a lack of flow exerted on 
the endothelia resulting in poor cell morphology and a “leakier” barrier compared to in 
vivo data (Cucullo, Hossain et al. 2011, Prabhakarpandian, Shen et al. 2013, Czupalla, 
Liebner et al. 2014, Deosarkar, Prabhakarpandian et al. 2015, Helms, Abbott et al. 2016).  
Second, endothelial cells do not uniformly attach to the outer side of the insert, leaving 
gaps between the endothelial cells and the edge of the insert also resulting in increased 
permeability (Santaguida, Janigro et al. 2006). Third, an unstirred water later forms on 
the surface of the endothelia which results in increased permeability for hydrophilic drugs 
and decreased permeability for lipid soluble drugs (Barry and Diamond 1984, Korjamo, 
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Heikkinen et al. 2008, Korjamo, Heikkinen et al. 2009, Loftsson 2012, Ghosh, Scott et al. 
2014).  
 
Herein we characterize novel in vitro microfluidic models of the BTB and BBB 
using a co-culture of endothelial cells and astrocytes along with tumor cells.  This model 
incorporates flow during culture of the endothelia and has a micro-tubular lumen, which 
in other work has substantially reduced limitations seen in transwells (Neuhaus, Lauer et 
al. 2006, Cucullo, Marchi et al. 2011, Booth and Kim 2012, Griep, Wolbers et al. 2013, 
Herland, van der Meer et al. 2016).  This model is unique from other flow based models 
in that it allows for a co-culture or triple culture of relevant cells, it is easily duplicated, it 
is commercially available and provides a cost-effective solution for running multiple and 
parallel assays. 
 
3.2 Materials and Methods 
3.2.1 Microfluidic Device  
Co-Culture idealized microvascular networks used in this study were obtained 
from SynVivo Inc. Huntsville, AL. The device consists of a central compartment 
(basolateral) that is comprised of the brain tissue cells (astrocytes, pericytes, neurons) and 
the outer compartment (apical) that is comprised of the endothelial cells and provides 
perfusion similar to physiological fluid flow conditions. The outer compartments and 
central compartment are separated by an interface with a series of 3 µm pores along the 
length, replacing the use of membranes in conventional models.  
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3.2.2 Chemicals  
Sulforhodamine 101 Acid Chloride (Free TRD), Rhodamine-123 (Rho123), Texas 
Red 3000 MW Dextran (TRD 3 kDa) and Texas Red 70,000 MW Dextran (TRD 70 kDa) 
were purchased from ThermoFisher Scientific (Grand Island, NY). Verapamil was 
purchased from Sigma (St. Louis, MO). Cyclosporine A was purchased from Toronto 
Research Chemicals Inc. (Toronto, Canada). All other chemicals used were of analytical 
grade and were used as supplied. 
 
3.2.3 Cell Culture  
Human Umbilical Vein Endothelial Cells (HUVECs) were purchased from Lonza 
(Allendale, NJ). CTX-TDR2 rat brain astrocyte cell line was kindly donated by Dr. Jim 
Simpkins (West Virginia University, Morgantown, WV). Met-1 murine metastatic breast 
cancer cells were a kind gift from Dr. Alexander Borowsky (UC Davis, Sacramento, 
CA). All cells were maintained in Endothelial Basal Medium – 2 (EBM-2) supplemented 
with the EGM-2 BulletKit from Lonza (Allendale, NJ). Cells were grown in a 37˚C 
humidified incubator with 5% CO2 until ~85% confluent. 
 
3.2.4 Cell Culture in Microfluidic Chip  
 Matrigel (40ug/cm2, EMD Milipore, Billerica MA) was injected into the central 
compartment and allowed to sit covered in ice for approximately 1 hour, after which 
serum-free media was promptly injected to wash the central compartment. Fibronectin 
(200 µg mL-1, EMD Milipore, Billerica MA) was then injected in one of the outer sides 
of the device and allowed to incubate at 37˚C overnight. Prior to the seeding of all cells, 
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the device was flushed with EBM-2 media. Astrocytes/Met-1 cells were harvested using 
TrypLE Select (ThermoFisher, Waltham MA) and re-suspended into a final concentration 
of ~1 X 107 mL-1 cells for injection, and were seeded at a flow rate of 10 µL/min in the 
central compartment using a Pump 11 Elite Nanomite programmable syringe pump 
(Harvard Apparatus, Holliston MA). The inlet port tubing was clamped when cells 
reached an intra-central compartment density of ~50% and chip was transferred to a CO2 
incubator at 37˚C and allowed to attach for 2 hours. HUVECs were harvested using 
TrypLE Select (ThermoFisher, Waltham MA) in the same process as described above, 
and re-suspended to a concentration of ~1 X 107 mL-1 and seeded into the outer 
compartment previously coated with Fibronectin at a flow rate of 6 µL/min using a Pump 
11 Elite Nanomite programmable syringe pump (Harvard Apparatus, Holliston MA). 
Inlet port tubing was clamped when HUVECs reached an intra-outer compartment 
density of ~90%, then chip was transferred to a CO2 incubator at 37˚C and allowed to 
attach for 24 hours. After 6 hours of incubation, medium in central and both outer 
compartments was replaced with fresh EBM-2 medium and repeated again at 24 hours. 
Astrocyte/Met-1 cells were maintained in the central compartment under static conditions in 
EBM-2 medium while EBM-2 medium was prepared in syringes mounted on a 
programmable PHD 2000 syringe pump (Harvard Apparatus, Holliston MA), connected 
to the chips through ~ 12 inches of sterile Tygon tubing (Harvard Apparatus, Holliston 
MA). This medium was flowed at a flow rate of 0.02 µL/min over the seeded HUVECs in 
the outer compartment for 4 hours, then increased to 0.05 µL/min after 4 hours, and finally 
to 0.1 µL/min after 4 more hours, maintaining a flow of 0.1 µL/min for 24 hours.  
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3.2.5 In vitro transport studies 
EBM-2 Medium was incubated in a BD Luer-Lok Syringe with either Free TRD 
(600 mg/mL), TRD 3 kDa (600 mg/mL), TRD 70 kDa (600 mg/mL), or incubated with 
Rho123 (600 mg/mL) in the presence or absence of known P-glycoprotein (p-gp) 
inhibitors (verapamil: 50 mM, cyclosporine A: 10 mM) and mounted on a programmable 
PHD 2000 syringe pump (Harvard Apparatus, Holliston MA), with syringes connected to 
the chips through sterile Tygon tubing (Harvard Apparatus, Holliston MA). Permeability 
was measured through the injection of desired tracer into the outer compartment at 0.1 
µL/min for a total of 90 minutes while brightfield images (acquired at a 25 ms exposure) 
and fluorescent images (acquired at a 200 ms exposure) were acquired every 2 minutes. 
Permeability of each tracer was determined using NIS Elements Imaging Software. Using 
linear regression (Prism 6.0), the slope of the best-fit line was used to represent the 
relative kin, or rate of accumulation, of fluorescence in the central compartment 
(comparable to the concentration of drug found in normal brain) divided by the 
accumulation of fluorescence in the outer compartment (comparable to the concentration 
of drug found in the plasma of the BBB vasculature). Unless otherwise stated, data are 
presented as mean ± S.E.M.  
 
3.2.6 Quantification of fluorescent tracers using fluorescent microscopy  
Chips were mounted on an automated stage enclosure, maintained at 37˚C with 
5% CO2, on a Nikon Eclipse TE2000-E Live Cell Sweptfield Confocal microscope 
(Melville, NY). Acquisition of images and fluorescence was achieved through the 
utilization of a Photometrics CoolSnap HQ2 Monochrome CCD Camera (Tucson, AZ) 
47	
with a 20x/0.75 Plan Fluor Phase Contrast objective with a total field of 6X8, stitching 
images using brightfield with a 10% overlay. Brightfield and fluorescent images were 
taken every two minutes for 90 minutes. Excitation and emission of Free Texas Red, 
Texas Red 3 kDa and 70 kDa, was obtained using the TRITC epiflourescence filter (peak 
fluorophore excitation is 596 nm and emission is 615 nm); excitation filter wheel of 
555/25x, emission filter wheel of 605/52m and dichromatic mirror at 89000 sedat quad. 
The excitation and emission of Rho123 (+/- cyclosporine A or verapamil) was obtained 
using the FITC epiflourescence filter (peak fluorophore excitation is 511 nm and 
emission is 534 nm); excitation filter wheel of 490/20x, emission filter wheel of 525/36m 
and dichromatic mirror at 89000 sedat quad. 
 
3.2.7 Kinetic analysis 
Unidirectional uptake transfer constants (kin) were calculated from the following 
relationship to the linear portion of the uptake curve: 
   (CCC + CPF) / CPF = kin (t) + OC  (Equation 3.1) 
Where CCC is the sum intensity of fluorophore in the region of interest in the central 
compartment (au) at the end of perfusion, CPF is the sum intensity of fluorophore (au) in 
the region of interest within the outer compartment, t is the perfusion time in minutes 
from the time the device reached steady state, and OC is the calculated intercept (T = 0 
min; "outer compartment volume" (au)). Since the device took 22 minutes to reach steady 
state, t=0 minutes is 22 minutes after start of the experiment, but 0 minutes from the start 
of steady state. After the determination of a perfusion time where an adequate amount of 
fluorescent marker was allowed to pass into brain, while still remaining in the linear 
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uptake zone, kin was determined (Takasato, Rapoport et al. 1984, Smith and Takasato 
1986). 
 
3.2.8 Statistical Analysis 
The slope of the line (kin) was determined with linear regression using best-fit 
values. One-way ANOVA analysis and unpaired t test with Welch’s correction, followed 
by an F test to compare variances were used for the comparison of the kin values between 
unrestricted diffusion, BBB, and BTB among each tracer and with Rho123 in absence 
and presence of inhibitors. For all data, errors are reported as standard error of the mean 
unless otherwise indicated. Differences were considered statistically significant at the p < 




In this study we evaluate BBB and BTB transfer rates of Free TRD, Texas Red 3 
kDa, Texas Red 70 kDa, and Rho123 (with and without inhibitors) (Fig 3.1) in a novel 
microfluidic BBB and BTB model as validation to previously published literature 
(Mittapalli, Manda et al. 2013).  Briefly in this model, endothelial cells are seeded in the 
outer compartments, while astrocytes (BBB) or brain seeding breast cancer cells (BTB) 
are seeded in the central compartment. The porous architecture between the two 
compartments allows for cellular crosstalk and biochemical exchanges, while shear stress 
from perfusate flow facilitates development of endothelial morphology (Deosarkar, 
Prabhakarpandian et al. 2015).  Confocal brightfield images show the differences in 
49	
morphology between endothelial cells with and without flow (Fig 3.1B-C).  In order to 
verify a confluent 360o coating of endothelial cells within the outer compartment, we 
used a Nikon A1R Confocal on Eclipse TiE Microscope to acquire a 3D z-stack of the 
outer compartment. Utilizing this system, DAPI stained endothelial cells were imaged 
from the bottom (Fig 3.2A), through to the top (Fig 3.2B) showing HUVECs wrapping 
around the sides of the outer compartment (Fig 3.2C) connecting the HUVECs on the top 
to the HUVECs on the bottom, verifying confluent formation of a tubular in vitro 
microvasculature. 
 
In initial experiments, we determined unrestricted diffusion rates of different 
sized molecules, by perfusing solutes through microfluidic chips without endothelial cells 
or astrocytes/cancer cells. To quantify tracer accumulation, regions of interest were 
selected to determine sum fluorescence intensity in the outer compartment (ROI 136), 
central compartment (ROI 139), and background (ROI 165) over time (3.1D). ROI 165 
was taken to ensure data received in the outer and central compartments were significant 
when compared to the background sum fluorescence.  We observed (Fig. 3.3) that small 
tracers (< 1000 Da) had a diffusion rate of 22.8 ± 2.5 X 10-3, n=6, which was not 
significantly different compared to tracers of molecular weights between 3-5 kDa (22.1 ± 
8.5 X 10-3, n=3) and > 60 kDa (17.5 ± 4.2 X 10-3, n=3).  
 
In our next experiments, we qualitatively imaged Texas Red accumulation from 0 
– 90 min in the BBB model (Fig 3.4A-3.4D). Linear accumulation of the dye in the 
central chamber of the BBB model is quantitatively shown in Figure 3.4E. We then 
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determined kin values for each tracer in both the BBB and BTB model (Equation 3.1). 
Free Texas Red kin values (Fig 3.5A) for the BBB (2.5 ± 0.3 X 10-3, n=6) and BTB (13.1 
± 1.3 X 10-3, n=4) were significantly different (p < 0.05) between each other. Texas Red 
3 kDa values (Fig 3.5B) for the BBB (0.1 ± 0.1 X 10-3, n=3) and BTB (1.8 ± 1.0 X 10-3, 
n=3) and Texas Red 70 kDa values (Fig 3.5C) for the BBB (1.1 ± 0.9 X 10-3, n=3) and 
BTB (4.5 ± 2.4 X 10-3, n=3) were also significant (p < 0.05) when compared to the 
unrestricted diffusion kin but significance was not observed between the BBB and BTB 
models of these dyes. 
  
To determine if p-gp inhibitors alter the accumulation of p-gp sensitive 
fluorescent dye accumulation into the central compartment we perfused Rho123 in the 
absence and presence of p-gp inhibitors cyclosporine A (10 mM), and verapamil (50mM) 
(Mittapalli, Manda et al. 2013). We qualitatively observed an increase in dye 
accumulation in the central compartment over the course of 90 minutes in both the BBB 
(Fig 3.6A) and BTB (Fig 3.6B) models  (Fig 3.6C). Quantitatively, we observed a 14-
fold increase of Rho123 in the central compartment, in the presence of p-gp inhibitor 
verapamil (14.7 ± 7.5 X 10-3, n=3), and a significant (p < 0.05) eight fold increase of 
Rho123 with cyclosporine A (8.8 ± 1.8 X 10-3, n=3) when compared to control Rho123 
(0.6 ± 0.1 X 10-3, n=4) in the BBB model (Fig 3.6D). Similarly in the BTB model, a 
three-fold increase was observed in Rhodamine-123 permeability in the presence of p-gp 
inhibitor verapamil (10.3 ± 3.1 X 10-3, n=3), and a two-fold increase with cyclosporine A 





The results of the studies presented herein suggest that a novel microfluidic chip 
in part mimics the in vivo BBB and BTB with regard to passive permeability and efflux 
(Adkins, Mohammad et al. 2016). Importantly, this study demonstrates that perfusion 
flow through the luminal compartment improves endothelial function. This model also 
has potential to be used as in screening assays for drug discovery and development for 
central nervous system disease.  
 
Predominant in vitro BBB models have some key similarities. First, there is a 
presence of some type of “barrier” cell in a luminal or outer compartment (representing 
the vascular lumen). These cells range from primary or immortalized brain endothelial 
cells (most commonly rat, mouse, or human), peripheral endothelial (HUVECs), or stem-
cell derived cells (Stanimirovic, Bani-Yaghoub et al. 2015). These barrier cells typically 
express tight junction proteins, which seal the endothelial cells together and produce 
higher TEER values (Reese and Karnovsky 1967, Brightman and Reese 1969, Zlokovic 
2008). Second the models usually include the presence of a semipermeable basement 
membrane separating the outer (lumen) and central (brain side) compartments. Lastly, 
cells, typically astrocytes and or pericytes, are seeded in the central compartment in an 
effort to mimic the brain microenvironment. The addition of these cells provide cell to 
cell communication to the endothelial cells in the outer compartment, resulting in the 
formation of tighter barrier and an increase in TEER (Abbott 2002, Coisne, Dehouck et 
al. 2005, Garberg, Ball et al. 2005, Pardridge 2005, Pardridge 2007, Abbott, Patabendige 
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et al. 2010, Stanimirovic, Bani-Yaghoub et al. 2015, Helms, Abbott et al. 2016).  
Germane to this work, to re-create the BTB, astrocytes and or pericytes are replaced with 
tumor cells in the central compartment. In vivo, angiogenesis occurs with the 
establishment of tumor tissue, resulting in the presence of fenestrations, gaps between the 
endothelial cells, varied expression of efflux transporters, and an increase in permeability 
(Schlageter, Molnar et al. 1999, Plate, Scholz et al. 2012).  
 
The use of dyes has been a long-standing method to evaluate the integrity of the 
BBB and the breakdown of the BTB. (Ehrlich 1885, Hawkins and Davis 2005, Hawkins 
and Egleton 2006, Goldmann 1913). Some of the earliest work using dyes dates back to 
the the 19th century, where Paul Ehrlich and Edwin Goldmann intravenously injected 
water-soluble dyes and observed that the dyes did not have the ability to freely exchange 
between the vascular and brain parenchyma compartment (Ehrlich 1885),(Goldmann 
1913). Dyes have also been used as a tool to visualize and qualitatively measure the 
disruption at the BBB (Bakay, Ballantine et al. 1956, Schettler and Shealy 1970, da Costa 
1972, Nemeroff and Crisley 1975, Lin and Kormano 1977) as well as the BTB 
(Mittapalli, Manda et al. 2013, Adkins, Mohammad et al. 2016). Passive permeability 
dyes are a simple way to compare rates of diffusion between different models in vivo and 
in vitro.  
 
To measure the unrestricted diffusion (the absence of cells) of molecules from the 
outer chamber to the center chamber, we observed that the diffusion rates (kin), from the 
outer compartment to the central compartment, of all three sized molecules were not 
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significantly different from each other.  These data are consistent with previous work 
showing that if the diameter of each molecule being tested is at least 12x less than the 
barrier defects, then diffusion will remain constant for all molecules (Nakagawa, 
Groothuis et al. 1987).  
 
An interesting aspect of our observations was the similarity of efflux function that 
existed in the microfluidic model compared to the in vivo BBB (Adkins, Mittapalli et al. 
2013). Rhodamine-123 is subject to p-gp mediated efflux at both the BBB and the BTB. 
When rho123 and an inhibitor of p-gp are administered concurrently, dye accumulates in 
brain ~10-12 fold higher than in the absence of efflux inhibition (Mittapalli, Manda et al. 
2013). Similarly, in this work when verapamil or cyclosporine A was added to the outer 
chamber of the microfluidic device, Rho123 accumulation increased similar to in vivo 
reports (Adkins, Mittapalli et al. 2013). Further, p-gp function retains function despite 
barrier breakdown in a number of pathologies (Cordon-Cardo, O'Brien et al. 1990, 
Adkins, Mittapalli et al. 2013). The data herein agree that the degree of efflux function 
for the BTB, though disrupted, is intact and it retains the ability to restrict drug and dye 
movement from the vasculature to the brain compartment. 
 
Transwells are a widely used in vitro method to study the BBB. Transwells are 
cheap, available in high throughput assays, and easy to use. However, there are 
substantial limitations. First, transport kinetics in transwell systems are strongly 
influenced by an unstirred water layer that exists on the outer side of the endothelial cells. 
The unstirred water layer will decrease the apparent permeability rate of lipid soluble and 
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to some extent water-soluble molecules.  Second, since the cells are grown in a static 
media there is no shear stress (or flow) forced on the endothelial cells, which may 
contribute to the low passive permeability measurements which can be as low as ~ 74 
ΩŊcm2 (Man, Ubogu et al. 2008), compared to in vivo values of ~ 2000 ΩŊcm2 (Crone and 
Olesen 1982). While a few other in vitro models and microfluidic devices have a flow 
component (Neuhaus, Lauer et al. 2006, Cucullo, Marchi et al. 2011, Booth and Kim 
2012, Griep, Wolbers et al. 2013, Herland, van der Meer et al. 2016) this microfluidic 
device is the first commercially available blood-tumor barrier using a microfluidic model 
utilizing brain-seeking cells with shear stress similar to in vivo (Deosarkar, 






Figure 3.1: Microfluidic chip schematic and methods. 
 
(A) Schematic of the SynVivo BBB Microfluidic Chip: (1) Inlet port where media with 
or without tracer is flowed through the outer compartment to change media for 
HUVECs.  (2) Outer Compartment, containing HUVECs. (3) 3 µm pores, to allow 
diffusion of media and tracer between the central and outer compartments. (4) Central 
Compartment, containing astrocytes or cancer cells. (5) Outlet port where perfusate from 
the outer compartment is collected. (6) Inlet port for central compartment, used to seed 
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and change media for the astrocytes/cancer cells in the central compartment. (7) Output 
ports where perfusate from the central compartment is collected. (B) Morphology of 
astrocytes in the central compartment and HUVECs in the outer compartment without the 
addition of flow (C) Morphology of astrocytes in the central compartment and HUVECs 
in the outer compartment with the addition of flow. (D) Representation of where the 




Figure 3.2: 3-D confocal image of DAPI labeled HUVECs in apical chamber. 
 
3-dimensional confocal images of DAPI labeled HUVECs in the outer compartment 
demonstrating a 360o coating of cells. The nuclei of the HUVECs are seen on the bottom 





Figure 3.3: Diffusion rates of different sized MW tracers in the same model.  
 
The diffusion rates of free MW tracers < 1000 Da (A), 3 – 5 kDa (B) and > 60 kDa (C) in 
an unrestricted, cell free microfluidic chips are shown. Statistical significance was 
determined using one-way ANOVA followed by Tukey’s multiple comparison tests, and 




Figure 3.4: Representative time-lapse images showing passive diffusion of Free TRD 
from the outer to the central compartment.  
 
Intensity of fluorescence increases linearly over time 0 min (A), 30 min (B), 60 min (C), 
and 90 min (D). (E) Linear concentration of tracer movement vs time to determine 






                         
                                                  
                         

















Figure 3.5: Linear central compartment accumulation of different tracers in the BBB and 
BTB microfluidic chip models. 
 
Linear central compartment accumulation of Free TRD (A), TRD 3kDa (B), and TRD 70 
kDa (C) in BBB and BTB SynVivo chip models. Images show rate of each tracer within 
each model. Statistical significance was determined using one-way ANOVA followed by 
Tukey’s multiple comparison tests, and student’s t-test; * p < 0.05 significance between 
tracer and unrestricted diffusion kin, n = 3-6; + p < 0.05 significance between BBB and 





Figure 3.6: Rhodamine-123 permeability with and without inhibitors in BBB and BTB 
models.  
 
Representative brightfield image of Rho123 dye accumulation in the central compartment 
after 90 minutes of perfusion in the BBB model without an inhibitor (A) and with an 
inhibitor (B). Rate of fluorescent dye accumulation of Rho123 into central compartment 
after 90 min of dye perfusion in BBB, and BTB chips (C). Rate of fluorescent dye 
accumulation in BBB (D) and BTB (E) chips perfused with Rho123 +/- p-gp inhibitors 
(cyclosporine A or verapamil). Statistical significance was determined using one-way 
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ANOVA followed by Tukey’s multiple comparison tests, and student’s t-test; * p < 0.05 
significance between tracer and unrestricted diffusion kin, n=3-4; + p < 0.05 significance 
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CHAPTER 4  
TRASTUZUMAB EFFICACY IN AN IN  VIVO  AND IN  VITRO  
MODEL OF BRAIN METASTASES OF BREAST CANCER 
 
4.1 Introduction 
Brain metastases are a fatal neurological complication of breast cancer which 
have historically been a major cause of morbidity. Women with symptomatic central 
nervous system (CNS) metastases have a median survival of approximately 4 months 
(Colzani, Liljegren et al. 2011). Furthermore, less than 2% of women survive two years 
post-diagnosis (Zimm, Wampler et al. 1981). The risk of developing brain metastasis has 
been reported to range from 10 to 16 % among advanced-stage breast cancer patients, 
making it the second most common cause of metastatic brain tumor after lung cancer 
(10–25%) (Palmieri, Smith et al. 2006, Park, Park et al. 2009, Steeg, Camphausen et al. 
2011, Lin 2013, Yeh, Yu et al. 2015).  
 
Among the many associated risk factors in the development of brain metastases 
from breast cancer, hormone receptor status is one of the most important (Sanchez-
Munoz, Plata-Fernandez et al. 2013). Within the HER2-positive subset, hormone receptor 
status appears to further define the risk of CNS relapse. Patients with hormone receptor-
negative/HER2-positive tumors experience increased risk of the CNS as site of first 
relapse as compared to patients with hormone receptor-positive/HER2-positive tumors 
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(Bendell, Domchek et al. 2003, Palmieri, Bronder et al. 2007, Leyland-Jones 2009, Vaz-
Luis, Ottesen et al. 2012). Up to 37% of patients with HER2-positive breast cancer 
relapse due to intracranial metastases, despite control of the peripheral tumors (Clayton, 
Danson et al. 2004, Witzel, Oliveira-Ferrer et al. 2016). Palmieri et al. demonstrated that 
Her-2 overexpression increases the outgrowth of metastatic tumors cells in the brain in 
breast carcinoma cell lines (Palmieri, Bronder et al. 2007). A limiting factor in the 
treatment of brain metastases is the inability of chemotherapy to reach the desired tumor 
location. This is due, in large part, to the presence of a strictly controlled and regulated 
complex network known as the blood-brain barrier (BBB). 
 
The BBB is a physical and functional barrier limiting passive diffusion of 
extrinsic agents into brain (Ballabh, Braun et al. 2004, Dauchy, Miller et al. 2009, 
Abbott, Patabendige et al. 2010, Cook and Freedman 2011). The BBB is mainly formed 
of endothelial cells, in addition to pericytes, astrocytes and neuronal cells that play an 
important role in the function of the BBB (Rip, Schenk et al. 2009). BBB endothelial 
cells have specific characteristics, such as the expression of tight junctions, which prevent 
passive paracellular transport of most water soluble compounds and many lipid soluble 
compounds with the exception of small gaseous compounds like carbon dioxide and 
molecular water (Ballabh, Braun et al. 2004, Hawkins and Davis 2005, Rip, Schenk et al. 
2009, Abbott, Patabendige et al. 2010, Abbott and Friedman 2012, van Tellingen, Yetkin-
Arik et al. 2015). 
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The function and organization of the BBB may be altered under pathological 
conditions. In the case of tumors, the BBB’s structure and integrity are altered forming 
the “Blood-Tumor Barrier” (BTB) (van Tellingen, Yetkin-Arik et al. 2015). The BTB 
differs from the BBB in its decreased tight junction expression (Liebner, Fischmann et al. 
2000), a disruption of the basement membrane (Deo, Theil et al. 2013) and an increase in 
permeability (Tate and Aghi 2009, Puhalla, Elmquist et al. 2015). However, radiologic 
data have shown that not all brain metastases display elevated BTB permeability (Lin, 
Bellon et al. 2004). The changes in BTB vascular permeability are typically 
heterogeneous throughout the tumor site (Lockman, Mittapalli et al. 2010, Villanueva 
2013). It has been observed that brain metastases from HER2+ breast cancers infiltrate 
brain parenchyma without disrupting the BBB, unlike brain metastases from triple 
negative or basal-type breast cancers, which often disrupt the BBB (Yonemori, Tsuta et 
al. 2010, Vaz-Luis, Ottesen et al. 2012, Witzel, Oliveira-Ferrer et al. 2016). Targeted 
therapies have revolutionized cancer treatment, potentially offering an improved 
therapeutic ratio (Boskovitz, Wikstrand et al. 2004), such as small molecule inhibitors 
(Hoelder, Clarke et al.)  and monoclonal antibodies (Boskovitz, Wikstrand et al. 2004). 
However, the ability of these drugs and antibodies to permeate the brain and brain 
metastases is highly debated. 
 
In this work, we have tested the permeability of I125-trastuzumab in an in vivo, and 
fluorescent trastuzumab-Rho123 (t-Rho123) in a novel in vitro model of brain metastases 
of breast cancer. This is one of the first studies to measure antibody movement across the 
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blood-brain and blood-tumor barriers, demonstrating accumulation of trastuzumab in 
brain metastases of breast cancer with confirmatory experiments in vitro. 
 
4.2 Materials and Methods 
4.2.1 In Vitro Studies: 
4.2.1.1 Chemicals and Reagents 
Texas Red 70,000 MW Dextran (TRD 70 kDa) was purchased from Molecular 
Probes (Invitrogen, Carlsbad, CA). Trastuzumab (Herceptin®, Genentech/ Roche) was 
buffer-exchanged into 50 mM potassium phosphate buffer and 150 mM sodium chloride 
adjusted to pH of 6.7. Trastuzumab was fluorescently linked to Rhodamine-123 (Innova 
Biosciences, Babraham, England).  All other chemicals are of analytical grade and were 
purchased from Sigma-Aldrich (St. Louis, MO). 
 
4.2.1.2 Cell culture for in vitro studies 
Human Umbilical Vein Endothelial Cells (HUVECs) were were purchased from 
Lonza (Allendale, NJ). CTX-TDR2 rat brain astrocyte cell line were harvested, 
expanded, and generously provided by the laboratory of Dr. Jim Simpkins (West Virginia 
University, Morgantown, WV). Both HUVEC and astrocyte line were cultured and 
maintained in Endothelial Basal Medium – 2 (EBM-2) with the supplementation of 
EGM-2 BulletKits from Lonza (Allendale, NJ). The laboratory or Dr. Patricia Steeg, of 
the National Cancer Institute, generously provided a JIMT-1 brain metastases of breast 
cancer cell line, a line which naturally overexpresses HER2+. These cells were cultured 
and maintained in DMEM supplemented with 10% Fetal bovine serum and 1% penstrep. 
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All cell lines for in vitro studies were grown within a 37˚C humidified incubator with 5% 
CO2 until ~85-90% confluent. 
 
4.2.1.3 Cell Culture in Microfluidic Chip 
The co-culture idealized microvascular microfluidic chips used in this study were 
obtained from SynVivo Inc (Huntsville, AL). These microfluidic chips were prepared, 
then cultured with cells and maintained as previously described (SynVivo, Chapter 3) 
(Prabhakarpandian, Shen et al. 2013).  
 
4.2.1.4 Transport studies and quantification using fluorescent microscopy 
For each device, a BD Leur-lok syringe connected to Tygon tubing was filled with EBM-
2 media containing fluorescent tastuzumab and mounted on a programmable Harvard 
PHD 2000 syringe pump (Harvard Apparatus, Holliston, MA). Chips were maintained at 
37˚C with 5% CO2 and mounted in an automated stage enclosure on a Nikon Eclipse 
TE2000-E Live Cell Sweptfield Confocal microscope (Melville, NY). Permeability was 
measured through the perfusion of fluorescently labeled trastuzumab through the outer 
chamber at 0.1µL/min. Brightfield (25 ms exposure) and TRITC (200 ms exposure) 
images were acquired every two minutes for 90 minutes with a Photometrics CoolSnap 
HQ2 Monochrome CCD Camera (Tucson, AZ) with a 20x/0.75 Plan Fluor Phase 
Contrast objective with a total field of 6X8, stitching images using brightfield with a 10% 
overlay. Following acquisition, NIS Elements Imaging Software was used to determine 
Regions of Interest (ROI) and data exported to Prism 6.0. A line of best fit was 
determined using linear regression (Prism 6.0), and the slope represents the relative rate 
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of accumulation of fluorescence (kin) in the central chamber (representing drug 
concentration found in normal brain) divided by the amount of fluorescence in the outer 
chamber (representing drug concentration found in the BBB/BTB vasculature). Unless 
otherwise noted, data are presented as mean ± S.E.M.  
 
4.2.1.5 Kinetic analysis 
Unidirectional uptake transfer constants (kin) were calculated using the following 
equation: 
   (CCC + CPF) / CPF = kin (t) + OC  (Equation 4.1) 
Where CCC is the sum intensity of fluorophore in the region of interest in the central 
compartment (au) at the end of perfusion, CPF is the sum intensity of fluorophore (au) in 
the region of interest within the outer compartment, t is the perfusion time in minutes 
from the time the device reached steady state, and OC is the calculated intercept (T = 0 
min; "outer compartment volume" (au)). Since the device took 22 minutes to reach steady 
state, t=0 minutes is 22 minutes after start of the experiment, but 0 minutes from the start 
of steady state. After the determination of a perfusion time where an adequate amount of 
fluorescent marker was allowed to pass into brain, while still remaining in the linear 
uptake zone, kin was determined (Takasato, Rapoport et al. 1984, Smith and Takasato 
1986). 
 
4.2.1.6 Statistical Analysis 
Using linear regression with best-fit values, the slope of the line (kin) was determined. 
One-way ANOVA analysis, unpaired student t test’s with Welch’s correction, and an F 
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test to compare variances were used for the comparison of kin values between the 
unrestricted diffusions, BBB, and BTB models,. For all data, errors are reported as 
standard error of the mean unless otherwise indicated. Differences were considered 
statistically significant at p < 0.05. (GraphPad Prism version 6.00 for Mac, GraphPad 
Software, San Diego, CA, USA). 
 
4.2.2 In Vivo Studies: 
4.2.2.1 Chemicals and reagents  
Texas red conjugated 625 MW dextran (TRD 625 Da) was purchased from Molecular 
Probes (Invitrogen, Carlsbad, CA). Trastuzumab (Roche) was buffer-exchanged into 50 
mM potassium phosphate buffer and 150 mM sodium chloride adjusted to pH of 6.7. 
Trastuzumab was radiolabeled with 125I.  All other chemicals are of analytical grade and 
were purchased from Sigma-Aldrich (St. Louis, MO). 
 
4.2.2.2 Cell culture 
Human MDA-MB-231-HER2+ metastatic breast cancer cells expressing enhanced green 
fluorescent protein (eGFP) and the luciferase construct, were cultured in DMEM 
supplemented with 10% fetal bovine serum and zeocin (300 µg/ml). Cells were harvested 
at 80% confluency for intracardiac injection. All cell lines were generously provided by 
the laboratory of Dr. Patricia Steeg at the National Cancer Institute. 
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4.2.2.3 Experimental brain metastases model 
Homozygous Female NuNu (n=20) mice were obtained from Charles River Laboratories 
(Kingston, NY) and used for all experiments in this study. All animals were 6–8 weeks of 
age at the initiation of the metastases models and were housed in a barrier facility. All 
studies were approved by the Animal Care and Use Committee at Texas Tech University 
Health Sciences Center and conducted in accordance with the 1996 NIH Guide for the 
Care and Use of Laboratory Animals. Mice were anesthetized with 2% isoflurane and 
inoculated with 175,000 breast cancer cells in the left cardiac ventricle with the aid of a 
stereotaxic device (Stoelting, Wood Dale, IL). The inoculum circulates in the peripheral 
vasculature, arrests in brain capillaries, extravasates across the blood-brain barrier (BBB), 
and mice develop metastatic lesions predominantly in the brain (Lockman, Mittapalli et 
al. 2010).  After intracardiac injection, mice were placed in a warmed (37 °C) sterile cage 
and their vitals monitored until fully recovered. Metastases were allowed to develop and 
visualized with bioluminescent imaging, until neurologic symptoms appeared (~32 days), 
and animals were anesthetized with ketamine/xylazine (100 and 8 mg/kg respectively) 
prior to injection with 125I-trastuzumab via IV bolus dose (femoral vein). 125I-trastuzumab 
was allowed to circulate for 24h. TRD 625 Da was injected intravenously (femoral vein). 
10 minutes’ post-injection, blood samples were obtained and mice were euthanized 
decapitated. 
 
4.2.2.4 Harvesting of the brain and other tissues and organs 
Animals were euthanized, brain tissue rapidly removed (less than 60 seconds), and placed 
in isopentane (-65°C). Brains were sliced (20 µm) using a cryostat (Leica Microsystems, 
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Wetzler, Germany), and sections were mounted on charged gold plated glass slides, air 
dried, and stored at -80 °C. In addition to the brain, blood and samples from other organs 
(heart, lungs, liver, spleen, kidney) were collected, washed, and weighed for comparative 
analysis. Radioactivity was measured immediately following collection (Tri-CARB 
2900TR, Perkin Elmer) and expressed as cpm/mg then converted to nCi/g. Distribution 
ratios are expressed as the amount of radioactivity in the tissue/blood normalized by 
weight. 
 
4.2.2.5 Quantitative autoradiography (QAR) 
Slides were placed in QAR cassettes (FujiFilm Life Sciences, Stamford, CT) along 
with 125I autoradiographic standards (Amersham Biosciences). A phosphor screen 
(FujiFilm Life Sciences, 20 × 40 super-resolution) was placed on the slides and standards 
and allowed to develop for up to 14 days. QAR phosphor screens were developed in a 
high-resolution phosphor-imager (FUJI FLA-7000, FujiFilm Life Sciences) and 
converted to digital images. Digital QAR images were calibrated to 125I standards and 
analyzed using MCID Analysis software (InterFocus Imaging LTD, Linton, Cambridge, 
England). Metastases permeability fold-changes were calculated based on 125I signal 
intensity within confirmed metastases locations (determined by eGFP fluorescence image 
overlays) relative to 125-I signal intensity in normal brain. 
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4.2.2.6 Fluorescence measurement  
Texas red fluorescence was imaged using a DsRed sputter filter (excitation/band λ 
545/25 nm, emission/band λ 605/70 nm and dichromatic mirror at λ 565 nm) (Chroma 
Technologies, Bellows Falls, VT) and eGFP (expressed in MDA-MB-231BR-HER2+) 
using an ET-GFP sputter filter (excitation/band λ 470/40 nm, emission/band λ 525/50 nm 
and dichromatic mirror at λ 495 nm) (Chroma Technologies, Bellows Falls, VT). 
Fluorescence image capture and analysis software (SlideBook 5.0; Intelligent Imaging 
Innovations Inc., Denver, CO) was used to obtain and quantify fluorescence images. 
Texas red permeability fold-changes were determined by Texas Red Sum intensity (SI) 
per unit area of metastases relative to the SI per area of contralateral normal brain 
regions. If metastases occurred in contralateral regions, adjacent slices containing 
unaffected tissues of the same brain structure were used as comparative normal brain 
regions. 
 
4.2.2.7 Unidirectional uptake transfer constants (Kin) 
Kin values were then calculated from brain distribution volume versus time as 
previously described (Lockman, Mittapalli et al. 2010). 
 
4.2.2.8 Bioluminescent imaging  
Mice were injected with D-luciferin potassium salt (150mg/kg; PerkinElmer, 
Waltham, MA) dissolved in sterile 1X PBS via intraperitoneal (IP) injection and then 
anesthetized with 2% isoflurane. Fifteen minutes after IP injection of D-luciferin, 
darkfield images of mice were acquired with an IVIS Lumineer XV (PerkinElmer) to 
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detect bioluminescence. Animals were imaged 1, 3, 6, 9, 12, 24, 48, 72, 96, 120, 144, and 
168 hours post intracardiac injection to ensure successful tumor injection and growth. 
 
4.2.2.9 Data analysis 
Statistical significance was determined by Student’s t-test and one-way ANOVA 
followed by Bonferroni’s multiple comparison’s tests. All differences were considered 
statistically significant at p< 0.05.  Data is reported as Mean ± Standard Deviation (SD) 
unless otherwise noted (GraphPad Prism 7.0, San Diego, CA).  Results associated with 
drug concentration in tumor and brain distant to tumor (BDT) are Mean values of 
combined readings from all tumor and BDT areas in the study group without separation 
by individual animal data. In the case of Kin analysis (Lockman, Mittapalli et al. 2010), 
values obtained at individual time points were also pooled together. 
 
4.3 Results 
To visualize in vitro movement of t-Rho123, microfluidic BBB and BTB chips 
(Fig. 4.1A) were established and utilized as previously published (Prabhakarpandian, 
Shen et al. 2013). The distribution of t-Rho123 in BBB and BTB models was analyzed. 
Using Equation 4.1, we observed a linear increase of fluorescent trastuzumab uptake in 
both the BBB (0.27 ± 0.33 X 104) (Fig. 4.1C) and BTB (1.29 ± 0.93 X 104) (Fig. 4.1D) 
models significantly greater than 0 (p < 0.05). The rate of movement of fluorescent 
trastuzumab was quantified through the addition of a region of interest in the outer 
chamber (comparative to concentration of drug in plasma, CPF) and a region of interest in 
the central chamber (comparative to concentration of drug in brain, CCC), then divided by 
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the sum intensity of tracer in the outer chamber (CCC + CPF / CPF) and plotted over time. 
The slope of this line, Kin (µL/min/µm2), was plotted and graphed (Fig. 4.1B) as the 
mean ± S.E.M. for the BBB (0.18 ± 0.05, n=3) and BTB (2.12 ± 1.36, n=3) models. Both 
the Kin for the BBB models as well as the heterogeneity of the Kin values in the BTB 
models were comparable to in vivo. The BBB (p<0.0033) and BTB (p<0.0005) models 
were significantly different in comparison to the unrestricted diffusion Kin of this model, 
as previously described (SynVivo, Chapter 3). 
 
Organ distribution of trastuzumab after intracardiac (left ventricle) injection of 20 
Nu/Nu mice with the HER2+ breast cancer cell line was determined. After the mice were 
developed metastases (~32 days), radio-labeled 125I-trastuzumab was injected and 
allowed to circulate, followed by the administration of TRD 10 minutes prior to 
decapitation. Quantitative autoradiography (QAR) was used to measure the brain tissue 
distribution of 125I-trastuzumab. Figure 4.2A represents organ distribution of 125I-
trastuzumab, variability in different body organs is observed. 125I-trastuzumab was found 
in significant quantities in spleen (5.04%, SD= 3.91), lungs (4.45%, SD= 2.08), liver 
(3.54%, SD= 2.26), kidney (3.12 %, SD= 2.06), and heart (3.08%, SD= 1.78) compared 
to normal brain (0.30%, SD= 0.22) and tumor brain tissues (0.46%, SD= 0.46). The 
accumulation of 125I-trastuzumab in tumor brain was 1.5 fold higher than normal brain 
tissue (p<0.0001) (Fig. 4.2B). 
 
Heterogeneous and limited distribution of 125I-trastuzumab in a preclinical brain 
metastases of breast cancer model is shown in Figure 4.3A- 4.3C. Metastases were 
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categorized into four groups based upon the magnitude of permeability change compared 
to normal brain; where low, intermediate, medium and high corresponds to < mean brain 
+ 3xSD; > mean brain + 3xSD but < 2 fold; 2-4 fold; high is > 4 fold, respectively. The 
mean and standard deviation of the four groups were, 1.30 and 0.34 for low permeability, 
1.88 and 0.07 for intermediate permeability, 2.79 and 0.61 for medium permeability, and 
7.40 and 4.66 for high permeability (Fig. 4.3D). 
 
Fold increase in 125I-trastuzumab (over normal brain) was plotted versus 
metastasis size (mm2) in individual 231-Br-Her2 brain metastases (Fig. 4.3E). No clear 
correlation was found between the size of brain metastases and the amount of 125I-
trastuzumab localized (Fig. 4.3E). Kin values were determined separately for normal and 
tumor areas of the brain (Fig. 4.3F). Mean Kin for normal brain tissue was 1.457x107 
mL/sec/g (SD= 0.55) while mean Kin in the case of tumor brain was 3.80 mL/sec/g (SD= 




Treatment of brain metastases of breast cancer conventionally consists of surgery, 
whole brain radiation, stereotactic radiosurgery, chemotherapy, and/or biological 
therapies (Rostami, Mittal et al. 2016). Various chemotherapeutic agents have shown 
only a modest effect on survival due to their limited ability to cross the blood brain 
barrier (BBB) (Rostami, Mittal et al. 2016). In a preclinical study using two different 
models of brain metastases of breast cancer, most metastases exhibited some increased 
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BTB permeability in comparison to normal brain. However, BTB permeability remained 
poorly correlated with lesion size, and only  approximately 10% of lesions with the 
highest permeability exhibited cytotoxic responses to paclitaxel or doxorubicin 
(Lockman, Mittapalli et al. 2010). In low-grade gliomas, the BTB resembles a normal 
functioning BBB, while in high-grade gliomas, BTB is disrupted “leaky”, as it is 
characterized by major alterations of the normal vascular function, shown through 
contrast-enhanced MRI by Dhermain et al. (Dhermain, Hau et al. , van Tellingen, Yetkin-
Arik et al. 2015). However, the magnitude of this local disruption is unlikely to be 
sufficient to allow drug penetration in meaningful quantities, and is thus considered a 
major obstacle for drug delivery to the brain (Tzeng and Green 2013). 
 
Trastuzumab (Herceptin®, Genentech/ Roche), is a widely used humanized 
monoclonal antibody, for the treatment of HER2+ breast cancer due to its ability to 
recognize and bind to the extracellular juxtamembrane domain of HER2. Through this 
binding, trastuzumab is able to inhibit the proliferation, therefore survival, of HER2-
dependent tumors (Park, Park et al. 2009). The ability of trastuzumab to significantly 
cross the BBB is unclear (Kute, Lack et al. 2004). Şendur et al (Sendur, Uncu et al. 2014) 
reported a case study using a combination of lapatinib and capecitabine followed by 
trastuzumab in HER2-positive brain metastatic breast cancer. No progression of cranial 
metastases was found post-treatment. In another case series by Mutlu et al (Mutlu and 
Buyukcelik 2015), one in three patients with HER-2 positive breast cancer brain 
metastasis maintained the brain metastases post-treatment with a combination of weekly 
trastuzumab plus vinorelbine. In an in vivo study by Kodack et al, it was observed that 
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through the use of a combination of a HER2 inhibitor with an anti–VEGF receptor-2 
antibody, trastuzumab, and lapatinib, tumor growth was significantly slowed in the brain, 
resulting in increased survival in a mouse model of HER2-amplified breast cancer brain 
metastasis using an orthotopic xenograft of BT474 cells (Kodack, Chung et al. 2012).  
 
In patients without brain metastases, the ratio of trastuzumab in plasma to 
trastuzumab in cerebrospinal fluid is > 300:1 (Pestalozzi and Brignoli 2000). Lampson 
found that monoclonal antibodies were able to reach brain metastases in only 2 models 
(Lampson 2011): blood-borne tumor from outside the brain, and dormant tumor that 
grows enough to rupture the BBB, and thus allow mABs to infiltrate. In addition to 
physical barriers, several functional barriers contribute to the restrictive nature of BBB, 
which represents a major obstacle to effective drug delivery into the CNS (Deeken and 
Loscher 2007). A group of efflux transporters (such as P-glycoprotein, breast cancer 
resistance protein, and multidrug resistance-associated proteins) are expressed on the 
brain endothelia, and collectively cause rapid efflux of a large group of lipophilic drugs 
from the CNS (Loscher and Potschka 2005). The use of novel P-glycoprotein inhibitors 
in enhancing BBB permeation, drug uptake, and retention has been an area of recent 
investigation (Andersson, Hansen et al. 2013, Andersson, Badisco et al. 2014, Bauer, 
Karch et al. 2015). 
 
This model has been previously used to observe small molecule movement and P-
glycoprotein efflux (SynVivo, Chapter 3). Through the utilization of this device, we 
observed a relatively similar fold increase of trastuzumab in vivo as compared to the in 
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vitro observation in the microfluidic device when comparing fold increases from the 
blood-brain barrier to the blood-tumor barrier. The prediction and evaluation of the 
ability of various therapeutic and diagnostic moieties to cross the BBB and BTB, as well 
as brain uptake kinetics are critical to progress efficient brain metastases therapy and 
diagnosis from basic to translational research. Such knowledge is urgently needed for the 
early detection and management of high-risk brain metastases in patients. This study 
demonstrates that, though in minute quantities, trastuzumab does in fact cross the blood-
brain and blood-tumor barriers. The heterogeneity of antibody dispersion observed within 
the in vivo tumors mimics that seen in the in vitro tumor model. Expanding on these data, 
future work should include the use of additional antibodies used to treat brain metastases 




Figure 4.1: Mechanism of trastuzumab movement.  
 
Linear central compartment accumulation of 125I-trastuzumab in in vitro BBB and BTB 
microfluidic chip models. Representative image of model with TRITC labeled 125I-
trastuzumab flowing over HUVEC cells in the outer compartment and either astrocytes or 
JIMT-1 cancer cells in the central compartment (1A). Rate of 125I-trastuzumab movement 
in each model plotted against the unrestricted diffusion kin; ** p<0.0033 significance 
between BBB model and unrestricted diffusion kin, n=3; *** p<0.0005 significance 
between BTB model and unrestricted diffusion kin, n=3. All data represent mean ± 
S.E.M. Each model is significantly different than 0 (p < 0.05) (1B). Representative 
graphs of the rate of accumulation of 125I in the BBB (1C) and BTB (1D) microfluidic 
devices.  
























































Figure 4.2. The distribution of radiolabeled 125I –trastuzumab in various 

































































Figure 4.3. Heterogeneous and limited distribution of 125I-trastuzumab in 
preclinical brain metastases of breast cancer model. 
 
Representative images of location of eGFP labeled 231-Br-Her2 brain 
metastases (3A), brain accumulation of Texas Red 625 Da (3B) and 125I-
trastuzumab (3C) are shown, respectively. Metastases were categorized into 
four groups based upon the magnitude of permeability change compared to 
normal brain; where low, intermediate and high corresponds to less than 
mean brain + 3xSD; more than mean brain + 3xSD but <2 fold; 2-4 fold; and 
high is >4 fold, respectively (Values represent mean ± SD, n=251 metastases) 
(3D). Fold increase in 125I-trastuzumab (over normal brain) was plotted 























































































































(3E). The correlation was minimal with 125I-trastuzumab fold increase versus 
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CHAPTER 5  
CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Conclusions 
This dissertation set out to study the distribution and efficacy of 
chemotherapeutics in a novel, microfluidic, in vitro preclinical model of brain metastases 
of breast cancer. Chapter 2 is an in depth review of the current static and microfluidic in 
vitro models most commonly available to researchers. This review shows that a new, 
commercially available model that mimics in vivo is drastically needed for the 
advancement of blood-brain barrier (BBB) and blood-tumor barrier (BTB) research. This 
review article further set out to evaluate the performance of cell-based in vitro systems of 
the BBB. It was found to be very difficult to evaluate the performance of the plethora of 
different models used because of the lack of coherence in the research field. The authors 
therefore call for a more standardized method to evaluate the performance of the different 
in vitro systems developed as an effort to jointly bring the research field forward. In 
pursuit of a widely-applicable, cost-effective, and accurate in vitro model of the BBB and 
BTB at the brain, all of the discussed microfluidic evices must be taken into 
consideration.  
 
In chapter 3, we set out to validate a novel and dynamic microfluidic in vitro BBB 
model. Through various permeability studies, we found that the permeability of large 
molecule dextrans, as well as small molecule dextrans, and Rhodamine-123 (with and 
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without inhibitors) were characteristic and relatable to what is seen in vivo. The added 
shear stress exerted on the endothelial cells from the addition of flow eliminated the 
unstirred water layer and allowed for different tracers to be added and real-time followed 
from outer (apical) to central (basolateral) compartment. P-glycoprotein (p-gp) was also 
shown to be functional and intact in both BBB and BTB models, and relatable to current 
in vivo data. We found that this novel microfluidic in vitro device successfully mimicked 
the in vivo barrier in regard to shear stress, permeability, and efflux. Based on these 
characteristics, this microfluidic chip shows potential for use in BBB and BTB research. 
 
When it comes to drug and antibody distribution across the BBB and BTB, the 
literature is conflicting and this topic continues to be highly debated. Despite the partial 
breakdown of the barrier, the BTB still exhibits efflux transporters (and other BBB 
properties) to a highly functioning degree, causing difficulties in the delivery of most 
drugs. The aim of Chapter 4 was to test the distribution of trastuzumab in both an in vivo 
and in vitro model. This chapter demonstrates that, though in minute quantities, 
trastuzumab does in fact cross the blood-brain and blood-tumor barriers. The 
heterogeneity of the antibody dispersion observed within the in vitro tumors mimics that 
seen in the in vivo tumor model. Expanding on these data, future work should include the 
use of additional antibodies used to treat brain metastases of breast cancer, as well as the 





5.2 Future Directions 
Throughout this dissertation, specifically during the validation of the microfluidic 
chip in chapter 3, multiple obstacles occurred throughout the experiments, leading to 
months of troubleshooting and the redesigning of projects. However, due to these 
obstacles, we have worked diligently with the CFD Research Corporation to develop, 
bioengineer, and restructure multiple variations to the current microfluidic chip. The 
proposed bioengineering modifications (Fig. 5.1) will allow for a greater diversification 
in the types of experiments that will be able to be run through this chip, as well as helping 
validate this in vitro model even further.  
 
5.2.1 Engineering Modifications 
The biggest limitation with the current microfluidic chip is the inability to 
measure transendothelial electrical resistance (TEER) values across the different barriers. 
TEER is a quantitative technique used to measure integrity of the BBB and BTB, and 
allows for comparison between models. In vivo, the TEER of brain capillaries is ~2,000 
ohm*cm2 (Crone and Christensen 1981, Olesen and Crone 1983), where as the TEER of 
the standard in vitro static BBB transwell is 25 Ω cm2 (Booth and Kim 2012). We have 
worked thoroughly with CFD Research Corporation to redesign their microfluidic device 
to adequately measure real time TEER in a way as to not disrupt the cell culture 
conditions. In order to measure TEER, three different components are required; 1) ports 
for insertion of electrodes, 2) development of electrodes and 3) portable and cost-
effective instruments for real-time monitoring. Figure 5.2 shows a conceptual schematic 
of the design for TEER measurement with the circles indicating location for electrodes 
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insertion. Every in vitro model has the ability for a TEER value to be measured, allowing 
for the comparison of the tightness of that model’s barrier to in vivo so with this 
bioengineering modification, the ability of this microfluidic chip to create an substantial 
and significant BBB will be able to be measured and directly compared to all other in 
vitro, and in vivo, models. 
 
Initially, when the projects for Chapter 3 began, we incorporated the use of five 
different compounds, including small and large molecules as well as a couple 
radiolabeled chemotherapeutics to add to the validation of this model in regards to drug 
movement across the BBB and BTB. When we began to run the experiments, a limitation 
that we observed was the very small size of the recovery ports. This limited the recovery 
of radiolabeled compounds and consequently we could not complete analysis. In the 
current design of the chip, the entire apical chamber, from the input to the recovery port 
only holds 0.806µl, with the central chamber holding only 1.795 µl (Fig. 5.3). Because of 
this limitation, we began to formulate the basis for a modified chip with larger port and 
chamber volumes, in order to run radioactive experiments. The proposed CAD layout of 
the optimized design and parameters of the modified chip is shown in Figure 5.4. The 
modifications include the changing of the circular central chamber to an elongated 
chamber design, and lengthening the overall device, allowing it to span the entire 
microscope glass slide. With these modifications, perfusate samples will to 10-20µl of 
sample for perfusate analysis, allowing for the integration of a vast amount of varying 
compounds and drugs.  
 
107	
 The last engineering modification to this device is to modify the device in 
order to isolate metastatic cells with varying metastatic potential. The mechanism of 
tumor cell extravasation is unknown and has not been successfully studied in vitro. The 
extravasation of tumor cells has been previously shown with this microfluidic device (Fig 
5.5), though the mechanism has not been elucidated, due in part to the inability to retrieve 
individual, or selective, tumor cells from the device. The first step for future modification 
is to alter the central chamber to 1) allow for quantification of cells based upon metastatic 
potential and 2) be able to collect cells with varying metastatic potential for next 
generation sequencing. One of the most exciting aspects of this modification is that the 
genomic driving forces of BBB cancer cell extravasation would be understood through 
the experiments using next generation sequencing of cells that can cross the BBB 
endothelia. In order to isolate the cells for single cell populations, the system will be 
redesigned as shown in Figure 5.6. The output of the central chambers will be distributed 
into multiple channels to separate cells with different metastatic potential. Each of the 
channels will be injected into a sample tube for isolation and analysis. Figure 5.6 also 
shows examples of fluidic isolation for separation based on the outlets. This modification 
has the potential to lead to significant insights and potentially druggable targets for 
cancer cells invading brain, something that has not yet been studied. 
 
5.2.2 Biological Modifications 
Throughout my project I utilized Human Umbilical Vein Endothelial Cells 
(HUVECs) as my endothelial cells of choice due to their ability to be used until a high 
cell culture passage, and the relative ease in the culturing ability. However, it was 
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brought to our attention that HUVECs may not be the best model to use in vitro to mimic 
the in vivo BBB. So to address this, we have postulated modifications in the device to 
improve cell culture conditions. Within these modifications, it might be of interest to 
utilize Dr. Eric Shusta’s model. Shusta utilizes human pluripotent stem cells that are 
simultaneously co-differentiated to both neural and endothelial lineages. By doing this, 
these cells produce an embryonic brain-like in vitro micro-environment that generates 
human pluripotent stem cells-brain microvascular endothelia cells. These cells would be a 
great cell to use for recreating the blood-brain or blood-tumor barriers because these cells 
have been shown to possess BBB endothelial characteristics such as well-developed tight 
junctions, high TEER, low passive permeability, and active and polarized efflux 
transporters (Perriere, Yousif et al. 2007, Lippmann, Azarin et al. 2012), all 
characteristics that are important in the in vivo BBB.  
 
In addition to modifying the endothelial cells, other biological modifications can 
be utilized to further verify the model through the use of different brain metastases cells 
(human pluripotent stem cells, patient derived xenografts (PDXs), JimtBr cells and 
MDA-MB-231Br cells) to create various different brain microenvironments, as well as 
the study of the permeability of each cell line in vitro and to be able to compare to the 
relative in vivo data. As the incidence of brain metastases of breast cancer continues to 
increase, the need for affordable, accessible, and accurate portrayals of the in vivo BBB 
in the form of in vitro models also increases. It is our hope that through these 
modifications, these microfluidic chips will become a widely accepted in vitro model, 
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Figure 5.1: Microfluidic BTB device overall modifications 
 
Inlet ports where perfusion flow enters outer chamber (A) and central chamber (C). 
Apical chamber contains endothelial cells that communicate across 3µm pores with 
metastatic cancer cells in the central chamber. Outlet ports where perfusate from the outer 
























Figure 5.2: Re-engineering of the BTB microfluidic device to allow for real-time TEER 
measurements 
 
A schematic (Left) and an example set-up of the device for TEER measurement is shown 
(right). Silver chloride electrodes are threaded through Tygon tubing attached to the 







Figure 5.3: Port volumes of the current microfluidic device 
 
Inlet ports for the apical chambers (A,E), basolateral chamber (C) and outlet ports for the 
apical chambers (B,F) and basolateral chamber (D) are depicted with the respected 
volumes described.  
  
Port A to Port B 
Volume (same 
as E to F) = 
0.806 ul 
 
Port C to Port D 




= 3.409 ul 
The volume of 
the arc of the 
apical chamber 
= 0.058 uL  
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Figure 5.4: Proposed redesign for increased recovery port volumes of the microfluidic 
device 
 
A CAD layout of the design and parameters for the optimized BTB microfluidic device  
with the proposed redesign schematic of the BTB microfluidic device (Left) and the 







Figure 5.5: Tumor cell extravasation 
 





Figure 5.6: Isolation of different cells of varying metastatic potential  
 
Concept of multi-cellular architectures in the central chamber which can separate 
invading cells by degree of migration (top). Concept of multiple outlets from the central 
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• Demonstrated strong leadership in managing various research projects within the 
lab and among various coworkers. 
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